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ABSTRACT 
 
We had shown that overexpression of cyclooxygenase (COX)-2 in human, as well as 
murine breast cancer cells promotes tumor progression and metastasis by multiple 
mechanisms: host immune cell inactivation and stimulation of cancer cell migration, 
invasion, tumor-associated angiogenesis and lymphangiogenesis, which support blood-
borne and lymph-borne metastasis. Most of these events resulted from the activation of 
the prostanoid receptor EP4 by endogenous PGE2. Recently, by stable transfection of 
COX-2 cDNA into a non-metastatic COX-2 negative human breast cancer cell line, 
MCF-7, we showed that COX-2 induces phenotypic properties of stem-like or “tumor 
initiating cells” (TICs) in MCF-7-COX-2 cells, as defined by in vitro studies and 
validated in vivo. Through combined gene expression and microRNA (miRNA) micro 
array analysis, we identified two miRNAs (miR-526b and miR-655) that are up-regulated 
in MCF-7-COX-2 cells that are associated with a down-regulation of 14 target genes 
linked to tumor-suppressor functions. We hypothesize that these miRNAs are important 
for COX-2 mediated TIC associated functions in human breast cancer. As a first step, we 
validated their expression in several COX-2 disparate human breast cancer cell lines: 
MCF-7, MCF-7-COX-2, SKBR-3 (HER-2 over-expressing but COX-2 negative) and 
SKBR-3-COX-2. The expression levels of miR-655 were strongly correlated with COX-2 
mRNA expression in these cell lines. Furthermore, the migratory and invasive capacities 
of the cell lines went hand in hand with miR-655 expression.  Expression of miR-655 was 
markedly inhibited by treating MCF-7-COX-2 cells with a COX-2 inhibitor (NS398) or 
an EP4 antagonist (ONO-AE3-208), indicating that the expression depended on both 
COX-2 and EP4 activity.	  Finally, we discovered that cells derived from tumorspheres 
exhibited a dramatic increase in COX-2 expression in comparison to the cells grown as 
monolayer. We also found that the tumorspheres derived from MCF-7, MCF-7-COX-2 
and SKBR-3 overexpressed miR-655. These findings, taken together, fortify the notion 
that COX-2, EP4 and COX-2 induced miR-655 expression play important roles in 
promoting and maintaining the TIC phenotype in breast cancer cells.  
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1.1 Breast Cancer: An Overview 
Breast cancer is a malignant neoplasm that arises from the breast glandular tissue 
and often presents uniquely in each patient. Even though there have been advances in 
breast cancer diagnosis and treatment over the past few years, it is unfortunately the most 
common cancer among women in North America and there has been an insufficient 
change in mortality rate once the tumor has metastasized. Of those diagnosed, it is 
predicted that approximately one third of breast cancer patients will die of the disease 
given current treatment strategies (Canadian Cancer Statistics, 2011). Therefore, there is 
a pressing need to develop new treatment strategies and targeted therapies to manage this 
complex disease.   
Breast cancer classification is based on the invasiveness, point of origin in the 
mammary glandular system, proliferative potential, and hormone receptor status of the 
neoplasm. Breast cancer may arise from either the ducts, referred to as ductal carcinoma 
(most common), or the lobules that produce milk, which is referred to as lobular 
carcinoma. Ductal carcinoma in situ (DCIS), or intraductal carcinoma, is breast cancer in 
the lining of the milk duct that has not yet invaded nearby tissues (Silverstein et al., 
1996), but may progress to invasive cancer if left untreated. DCIS usually contain 
hormone-receptor positive cells that may respond to anti-hormone therapy and therefore 
have the best prognosis. Invasive ductal carcinoma (IDC) is the invasive variety of ductal 
carcinoma in which cancer cells have invaded through the basement membrane of the 
duct wall and into the fatty tissue of the breast, where they may metastasize via the 
bloodstream or lymphatic system to distant areas in the body (ACS, 2012). Lobular 
carcinoma in situ (LCIS) is a noninvasive form of lobular cancer. Unfortunately, patients 
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who are diagnosed with LCIS have an increased risk of invasive cancer in the same or 
both breasts (Simpson et al., 2005). Invasive lobular carcinoma (ILC) is the invasive 
form of lobular breast cancer and like IDC can metastasize.  
Breast cancer is highly curable by lumpectomy or mastectomy and adjuvant 
therapy, provided that it has not metastasized. Current established treatment strategies to 
delay the progression of metastasized breast cancer include cytotoxic chemotherapy, 
radiation therapy and targeted therapies (Hobday and Perez, 2005). Similar to many 
other types of cancers, breast tumors tend to metastasize initially into the regional lymph 
nodes, a process that typically is followed by dissemination into distant organs. 
Metastasis is a multistep process that is initiated by primary tumor cells invading 
adjacent tissue and entering the vasculature (intravasation) (Fidler, 2003). From the 
systemic veins, cells will typically be arrested in the pulmonary circulation, to 
extravasate into the lungs. In the case of the lymphatic system, cells will travel to 
regional lymph nodes or to the venous system to extravasate into the lungs. In the case of 
the portal venous system draining the gastrointestinal tract, cells will arrest and 
extravasate into the liver. However, hemodynamics is not the only determinant of the 
metastatic site. For example, both breast and prostate cancer can metastasize to bones, 
best explained by the “seed and soil hypothesis,” initially proposed by Paget in 1889 and 
revived by Fidler (2003). This hypothesis suggests that tumor cells (“seeds”) interact 
with a specific organ microenvironment (“soil”), and metastasis occurs when the seed 
and soil are compatible.  For example, chemokines made by the organ are believed to 
attract cancer cells with the appropriate chemokine receptors (Cheng and Hung, 2009). 
One well-studied chemokine is CXCL12 and its receptor CXCR4, which have been 
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shown to be involved in many cancers. CXCL12 is expressed in lung, liver, bone and 
lymph nodes where metastases are commonly located (Zlotnik, 2006).  
Breast cancer classification can also be based on the expression of certain 
receptors, which influence the severity of the neoplastic disease. The receptors used to 
classify breast cancer include; estrogen receptor (ER), progesterone receptor (PR), or 
human epidermal growth factor receptor 2 (HER2). The selective ER/PR+ tumors 
account for nearly 60-70% of diagnosed breast cancers, with the remaining 30-40% 
being split between HER2+ breast cancers and triple negative breast cancers (ER-, PR-, 
HER2-) (Slamon et al., 1989). Breast cancer classified as ER-positive is sensitive to 
estrogen and estrogen stimulation can lead to increased tumor growth. ER-positive 
cancer can therefore be treated by blocking this receptor and consequently the effect of 
this hormone. The selective ER antagonist tamoxifen and aromatase inhibitors are 
recommended as adjuvant endocrine therapy agents for the treatment of hormone 
receptor-positive early breast cancer (Sehdev et al., 2009). However, these agents are 
limited by their toxicity and moderate efficacy. HER2 positive patients have a more 
aggressive disease, a higher risk that the disease will recur and a higher propensity for 
metastasis to the brain (Serrano-Olvera et al., 2006). Trastuzumab is a recombinant 
humanized monoclonal antibody against HER2 protein that blocks the HER2-mediated 
activation of intracellular kinases and effectors (Valabrega et al., 2007). Although the 
combination of chemotherapy and trastuzumab prolongs survival in the adjuvant and 
metastatic settings, the majority of women with HER2+ metastasis disease will develop 
resistance to trastuzumab within one year of treatment or are not treatable with this agent 
because of cardiotoxicity. Triple negative breast cancer is considered the worst cancer 
	  	  
5	  
type because it tends not to respond to hormonal or HER2 based therapy. Although 
current treatment strategies are beneficial to some degree, future successful therapeutics 
must be directed toward multiple targets and individual patient subtypes.  
 Recently, gene expression profiling has been utilized to classify breast cancer for 
prognostic evaluation and therapeutic approaches.  Breast cancer subtypes are associated 
with distinctly different gene expression patterns detectable by microarray analysis 
(Sorlie et al., 2006). Studies have shown that ER-positive and ER-negative breast cancers 
are distinct diseases at the transcriptomic level and additional subtypes might exist 
within these groups (Reis-Filho and Pusztai, 2011). Using DNA expression profiling, 
Sorlie et al. have identified signature genes characterizing two subtypes, luminal A and 
basal-like, suggesting that distinct molecular mechanisms might have been pre-
programmed at an early stage in these particular subtypes (Sorlie et al., 2006). Gene 
expression profiling has created new laboratory methods, including a commercial tool 
called "Oncotype DX", which uses quantitative RT-PCR to measure the expression of 21 
genes (16 cancer-related and 5 reference genes). This can be performed with RNA 
extracted from tissue samples (Paik et al., 2004). “Oncotype DX” provides genetic 
information that can be directly used to predict the response of therapy and likelihood of 
recurrence in breast cancer patients with ER-positive disease and therefore aid in their 
prognosis. These results support the concept that breast cancer subtypes represent 
biologically distinct diseases that require unique therapeutic approaches.  
 Breast cancer is a heterogeneous disease and each patient’s tumor presents with 
unique characteristics. This fact has lead to a movement towards personalized targeted 
therapy for the treatment of breast cancer. Targeted therapy utilizes biomarkers and 
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combinations of marker signatures to improve the diagnosis, prognostic classification 
and prediction of therapeutic benefit and toxicity for individual patients. Two novel 
therapeutic targets that hold great promise in advancing breast cancer treatment include 
tumor-initiating cells (TICs) or cancer stem cells (CSCs), and microRNAs (miRNAs). 
Tumor progression, metastasis, as well as recurrence after therapy-initiated remission are 
all believed to result from a minor tumor cell subpopulation known as the  “Stem” or 
‘tumor-initiating cells” (TICs). MicroRNAs (miRNAs) are small regulatory RNAs that 
are emerging as biomarkers for cancer and other diseases (Khoshnaw et al., 2009). The 
involvement of TICs and miRNAs in the development of novel targeted breast cancer 
therapies will be discussed in later chapters.  
1.2 Prostanoids 
1.2.1 Prostanoid Pathway 
The prostaglandin E2 pathway and its mediators are currently under investigation 
for exploitation in breast cancer therapy (Figure 1). Prostaglandin E2 is a member of the 
prostanoid family. Prostanoids and leukotrienes are the two major divisions of the 
bioactive lipid compounds known as eicosanoids. Arachidonic acid (AA) is the precursor 
of the eicosanoids and is present in membrane bound glycerophospholipids. When cells 
receive an appropriate stimulus, either a secretory or cytoplasmic phospholipase A2 
(PLA2) is activated to cleave AA from the membrane and the free AA can serve as a 
substrate for the cyclooxygenase enzymes, cyclooxygenase-1 (COX-1) and 
cyclooxygenase-2 (COX-2).  COX-1 and COX-2 isozymes catalyze the first two steps in 
the synthesis of prostanoids from AA (Li et al. 2007). The COX enzymes carry out a 
two-step reaction, where they first oxidize AA to produce prostaglandin G2 (PGG2) and  
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Figure 1. Prostanoid Pathway. Following cellular activation, arachidonic acid (AA) is 
liberated from membrane phospholipids by phospholipase A2 (PLA2). AA is then 
converted to the intermediate precursor prostaglandin G2 (PGG2) by the action of 
cyclooxygenase (COX) enzymes. COX-1 is constitutively active, while COX-2 is 
inducible following an inflammatory stimulus. COX enzymes contain both COX activity 
and the peroxidase activity, which converts PGG2 to prostaglandin H2 (PGH2). PGH2 is 
then converted by different prostanoid synthases to various prostanoids, including 
prostaglandin E2 (PGE2). PGE2 elicits various signal transduction pathways by activation 
of one of the four EP receptor subtypes. All four EP receptors are G protein-coupled 
receptors. EP1 is coupled with phospholipase c inositol triphosphate signaling, leading to 
mobilization of intracellular calcium. EP2 and EP4 signaling both leads to activation of 
adenylate cyclase and increased cyclic AMP, via a Gs protein.  The distinctive 
stimulation of the PI3K/Akt pathway makes EP4 unique from the EP2 receptor.  EP3 is 
coupled to the inhibition of adenylate cyclase, via a Gi protein. (The pathway highlighted 
in red is the main focus of this project.) (Adapted from: Taketo, 1998, and Gualde & 
Harizi, 2004). 
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secondly carry out a hydroperoxidase reaction to convert PGG2 to prostaglandin H2 
(PGH2).  PGH2 is the common intermediate for the synthesis of the five primary series-2 
prostanoids: prostaglandin D2 (PGD2), prostaglandin E2 (PGE2), prostaglandin F2alpha 
(PGF2α), prostacyclin (PGI2) and thromboxane A (TXA2) (Figure 1). The type of 
prostaglandin produced is dependent on the cell-type specific prostaglandin synthase 
present, and in the case of PGE2 the appropriate synthase is prostaglandin E2 synthase. 
PGE2 plays physiological roles in inflammation, vasodilation, bone formation, 
hemostasis, wound healing, gastrointestinal epithelial integrity, and induction of labor 
(Li et al., 2007).  
 
1.2.2 Cyclooxygenase (COX)-2 and Cancer Therapy 
Three COX isozymes have been identified: constitutive COX-1, the inducible 
COX-2, and COX-3 (Xie et al., 1991). All mediate the conversion of AA to PGG2 and 
then to PGH2. COX enzymes are located on the luminal side of the endoplasmic 
reticulum membrane and on both inner and outer membranes of the nuclear envelope 
(Chandrasekharan and Simmons, 2004), and can free AA from phospholipids on the 
cytoplasmic side. COXs have short catalytic lifespans because they are autoinactivated.   
Unfortunately, not much is known about COX-3, other than that it is a splice variant of 
COX-1. COX-1 is constitutively expressed in virtually all tissues, including platelets, 
endothelial cells, cells of the gastrointestinal tract, and glomeruli among others (Xie et al., 
1991). 
 COX-2 transcription is inducible and is increased in response to certain growth 
factors, inflammatory cytokines, tumor promoters or endotoxins (Needleman and Isakson, 
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1997).  It is virtually undetectable in most tissues under basal conditions, but is inhibited 
at the level of transcription by glucocorticoids (Smith et al., 1994). COX-2 expression 
has also been reported in certain cells in the brain (Breder et al., 1995), lungs (Harris et 
al., 1994), kidney (Ermert et al., 1998) and reproductive organs (Lazarus et al., 2004). 
Since COX-2 is up-regulated in response to growth factors, tumor promoters and 
inflammatory associated cytokines (Herschman, 1996), it is significantly involved in 
tumorigenesis. Increased constitutive expression of COX-2 has been shown to be 
associated with many types of cancers, including breast, colorectal, lung, prostate, 
cervical, bladder, skin, head and neck, gastric and esophageal (Harris, 2003).  
 
1.2.3 COX Inhibitors 
Most cancers studied have increased levels of PGE2 and other arachidonate 
products (Karmali, 1980, and Eberhart et al., 1994). Inhibiting various parts of this 
pathway has shown therapeutic potential for numerous types of cancer, especially 
colorectal cancer (Wang and Dubois, 2006).  Analysis of COX expression in colorectal 
cancer revealed that COX-2 is up-regulated in 85% of colon carcinomas (Eberhart et al., 
1994). Nonsteroidal anti-inflammatory drugs (NSAIDs) such as aspirin inhibit both 
COX-1 and COX-2 and it is widely accepted that aspirin has an antineoplastic effect on 
colorectal tumors. Several epidemiological studies (US Preventative Services Force, 
2007), randomized controlled trials of colon polyp recurrence (Cole et al., 2009) and 
randomized trials in patients with hereditary colorectal cancer syndromes (Burn et al., 
2011) have shown that NSAIDs reduce incidence of colorectal neoplasia. Recently, 
Rothwell et al. (2012) showed that aspirin has a chemo-preventative benefit for other 
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cancer types. They showed that a daily aspirin dose was associated with a 21% reduced 
risk of cancer death with benefit only apparent after 5 years. In six primary prevention 
trials, Rothwell and colleagues also showed that low-dose aspirin reduced the risk of 
cancer incidence by 12% and reduced the risk of cancer with distant metastasis 
(Rothwell et al., 2012). Since NSAIDs inhibit both COX-1 and COX-2 isoforms, they 
may cause serious side effects, due to the loss of the physiologically important roles of 
COX-1, such as inhibiting the production of PGs in the gastrointestinal tract leading to 
peptic ulcer disease (PUD)(Needleman and Isakson, 1997). This has lead to the 
development of COX-2 specific inhibitor therapies for chronic inflammatory diseases 
and certain cancers. Celecoxib, a COX-2 specific inhibitor, is now approved adjuvant 
therapy in the treatment of colorectal cancer. Unfortunately, there are potentially serious 
side effects of COX-2 inhibitors such as an increased risk of atherothrombotic events, 
even with short-term use (Kearney et al., 2006). The PGE2 receptors (EP1, EP2, EP3 and 
EP4) may present as attractive alternatives because of their differential signaling 
abilities.   
 
1.2.4 COX-2 and Breast Cancer  
 In breast cancer, elevated COX-2 mRNA-expression has been reported to vary 
between 50% (Yoshimura et al., 2003) and 100% (Kirkpatrick et al., 2002) in the 
literature, with most studies reporting elevated expression in all tumors. The proportion 
of immunohistochemically identified COX-2 positive tumors varies between 4% (Hwang 
et al., 1998) and 85% (Kelly et al., 2002). COX-2 expression in human breast cancer 
correlates with reduced survival and also poor prognostic markers, such as increased 
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tumor size, high tumor grade, negative hormone receptor status, HER2 overexpression 
(Ristimaki et al., 2002), lymphangiogenesis (Timoshenko et al., 2006) and lymph node 
metastases (Costa et al., 2002 & Zhang et al., 2008). All of these earlier studies reveal 
the importance of COX-2 overexpression in the promotion of tumor progression and 
malignant behavior by multiple mechanisms. 
 Previous work in our lab has shown that selective COX-2 inhibitors reduced 
tumor cell migration and invasiveness in vitro (Rozic et al., 2001). It was further shown 
that COX-2 mediated promotion of cancer cell migration was at least in part mediated by 
endogenous PGE2, acting primarily via the EP4 receptor (Timoshenko et al., 2003). The 
side effects of COX-2 therapy has led to the search for alternate targets in the prostanoid 
pathway, including the selective inhibition of individual downstream PGE2 receptors, 
such as EP4. 
 
1.2.5 Prostaglandin E2 (PGE2) and Breast Cancer 
 PGE2 is the prostanoid most implicated in tumor progression, and its 
involvement is through multiple mechanisms. For example, PGE2 is involved in chronic 
inflammation (Schwartsburd, 2003) and has been shown to promote breast cancer 
progression by inactivation of host anti-tumor immune cells (Parhar & Lala, 1985 
and1986). PGE2 has also been shown to promote tumor cell migration and invasiveness 
(Rozic et al., 2001 and Mayoral et al., 2005) and inhibit apoptosis (Munkarah et al., 2002 
& Kawamori et al., 2003). Tumor derived PGE2 resulting from COX-2 expression by 
murine and human breast cancer cells was also revealed to stimulate tumor-associated 
angiogenesis (Rozic et al., 2001) and production of lymphangiogenic factors such as 
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VEGF-C (Timoshenko et al., 2006). PGE2 can also induce actin polymerization and 
epithelial-mesenchymal transition (EMT), leading to increased metastasis of cancers 
through activation of the PI3K/Akt pathway (Sheen et al., 2006). Furthermore, COX-2 
stimulation of VEGF-C production could also promote breast cancer cell migration by 
binding to a diverse family of VEGF-C receptors expressed by breast cancer cells 
(Timoshenko et al., 2007).  
 
1.2.6 EP Receptors 
 The prostaglandin E (EP) receptor expression profile of a cell determines the 
effects that PGE2 will exert on it. In mammals, there are four isotypes of G-coupled 
receptors that can bind to PGE2, known as EP1, EP2, EP3 and EP4 (Figure 1). EP1 is 
coupled with phospholipase C/inositol signaling, leading to mobilization of intracellular 
calcium (Tabata et al., 2002).  EP2 and EP4 signaling generates increased intracellular 
cyclic AMP (cAMP) levels (Sugimoto and Narumiya, 2007), while EP3 activation leads 
to a reduction in intracellular cAMP levels. However, EP2 and EP4 play distinct roles 
due to the fact that EP4 couples to phosphatidylinositol 3-kinase (PI3K/Akt) and EP2 
does not (Sugimoto and Narumiya, 2007 & Sheng et al., 2001). Multiple EP receptors 
have been implicated in various aspects of breast cancer development and progression: 
EP1 in mammary carcinogenesis (Kawamori et al., 2001); EP2 in COX-2 induced 
mammary hyperplasia (Chang et al., 2005); and EP4 in promoting invasiveness in an 
inflammatory type breast cancer cell line (Robertson et al., 2010). Our laboratory has 
reported that PGE2 increases migration of breast cancer cells through binding to the EP4 
receptor (Timoshenko et al., 2003). EP4 has likewise been shown to be responsible for 
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an up-regulation of iNOS gene expression under inducible conditions in murine breast 
cancer cells (Timoshenko et al., 2003).  Up-regulation of iNOS expression leads to 
increased invasive capacity (Timoshenko et al., 2004). COX-2-mediated up-regulation of 
the lymphangiogenic factor, vascular endothelial growth factor-C (VEGF-C), in human 
breast cancer cell lines was shown to be at least in part dependent on EP1 and EP4 
receptors (Timoshenko et al., 2006). EP4 antagonist ONO-AE3-208, but not EP1 
antagonist, was highly and equally effective as the COX-2 inhibitor Celecoxib in 
inhibiting primary tumor growth, tumor-associated angiogenesis and lymphangiogenesis, 
and metastasis to the lymph nodes and the lungs in a murine breast cancer model (Xin et 
al, 2012).  EP4 has also been shown to be up-regulated in macrophages in response to 
lipopolysaccharide (LPS) (Ikegami et al., 2001).  The well-defined roles that the EP4 
receptor plays in PGE2 mediated breast cancer progression makes targeting this 
particular receptor for the treatment of breast cancer very promising.  
 
1.3 MicroRNAs (miRNAs) 
1.3.1 Background: Biogenesis of miRNAs 
It is widely acknowledged that alterations in genes encoding proteins play a 
crucial role in cancer progression. Recent advancements in cancer research have unveiled 
that non-coding genes also significantly contribute to tumorigenesis (Calin and Croce 
2006, & Esquela-Kerscher and Slack 2006), revealing that the genomic complexity of 
cancer cells is far greater than anticipated. Small non-coding miRNAs are now known to 
be involved in the initiation and progression of human cancer and this knowledge may 
have a revolutionary impact on cancer diagnosis, therapy and monitoring. MiRNAs are 
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small regulatory, evolutionally conserved RNAs of 19-24 nucleotides (nt) in length that 
lead to silencing of their cognate target genes by post-transcriptionally cleaving their 
target mRNA or inhibiting their translation (Bartel, 2004). Each miRNA may repress 
hundreds of mRNA transcripts, but do not exert the same degree of repression on each 
mRNA. Furthermore, a single mRNA sequence may present numerous miRNA-binding 
sites.  It is estimated that miRNAs could target >30% of the human genome (Lewis et al., 
2005) and subsequently directly or indirectly control the expression of thousands of 
proteins (Lim et al., 2005) and regulate a large portion of the genome (Friedman et al., 
2009). Therefore, a disruption in the function of one miRNA could have exponential 
pathological consequences overall. 
MiRNA biogenesis begins in the nucleus where the miRNA gene is transcribed 
by RNA polymerase II or III to produce primary miRNA (pri-miRNA) (Figure 2). The 
pri-miRNA is cleaved by the RNase III enzyme Drosha, coupled with its binding partner 
DGCR8. The resulting precursor hairpin (pre-miRNA), consisting of approximately 70 
nt, is exported from the nucleus by Exportin-5-Ran-GTP. In the cytoplasm, the RNase 
enzyme Dicer cleaves the pre-miRNA hairpin into an unstable 19-25 nt miRNA duplex 
structure. The passenger strand (microRNA*) is then degraded. The functional strand of 
the mature miRNA is loaded together with Argonaute (Ago2) into the RNA-induced 
silencing complex (RISC). The miRNA-RISC-Ago2 complex then binds to the 3’UTR 
region of the target mRNA and silences the target mRNA through cleavage or 
translational repression (Figure 2).  
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Figure 2. Pathway of MicroRNA (miRNA) biogenesis and action. In the nucleus, the 
miRNA gene is transcribed by RNA polymerase II or III to produce primary miRNA 
(pri-miRNA). The pri-miRNA is cleaved by the RNase III enzyme Drosha, coupled with 
its binding partner DGCR8. The resulting precursor hairpin (pre-miRNA), consisting of 
approximately 70 nt, is exported from the nucleus by Exportin-5-Ran-GTP. In the 
cytoplasm, the RNase enzyme Dicer cleaves the pre-miRNA hairpin into an unstable 19-
25 nt miRNA duplex structure. The passenger strand (microRNA*) is degraded. The 
functional strand of the mature miRNA is loaded together with Argonaute (Ago2) into 
the RNA-induced silencing complex (RISC). The miRNA-RISC-Ago2 complex then 
binds to the 3’UTR region of the target mRNA and silences the target mRNA through 
cleavage or translational repression. (Adapted from: Bartel, 2004 and Kim, 2005) 
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1.3.2 MiRNAs and Breast Cancer 
MiRNAs control a wide array of physiological and pathological processes, 
including development, metabolism (Poy et al., 2004), differentiation (Chen et al., 2004), 
cellular proliferation, apoptosis (Bennecke et al., 2003), oncogenesis and metastasis 
(Filipowicz et al., 2008). This is achieved by modulating the expression of their target 
genes through imperfect base pairing with the target 3’ UTR mRNA and cleaving mRNA 
molecules or inhibiting their translation (Brennecke et al., 2005). Unique miRNA 
signatures are found in different tissue types as well as in different tumor types. Calin et 
al. (2004) have shown that miRNA genes are frequently located at fragile sites or 
common breaking points in the genome and are susceptible to amplification, deletion, or 
translocation during the course of tumor development. This supports the idea that 
miRNAs are extensively involved in cancer. These fascinating findings reveal a 
promising role for miRNAs in serving as important predictors of disease risk and 
progression and thereby aiding in the translation of research from the bench to the 
bedside (Andorfer et al., 2011).  
MiRNA expression signatures are being used advantageously to differentiate 
between tumor subtypes, tumor stage, receptor status, patient survival and the origin of 
metastatic tumors (Lu et al., 2005). MiRNAs that are abnormally expressed in cancer 
have great potential as biomarkers in the clinic due to their high resistance to degradation, 
extremely high stability in whole blood and serum and their ease of extraction and 
detection in patient samples (Andorfer et al., 2011). In particular, the stability of 
miRNAs in blood has evoked an emerging interest in utilizing miRNA profiling as a 
minimally invasive technique to aid in the diagnosis, prognosis and treatment of cancer. 
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Interestingly, it appears that circulating miRNAs elevated in the blood of cancer patients 
are derived from the primary tumor as removal of the primary tumor leads to the loss of 
the elevated levels of these miRNAs (Andorfer et al., 2011). 
  It has become apparent that alterations in miRNA expression contribute to breast 
cancer pathogenesis (Calin et al., 2004) and similar to genes, certain miRNAs can be 
classified either as oncogenic or tumor suppressive. This classification depends upon if 
the miRNA has the potential to cause cancer or protect cells from transformation into 
cancer respectively. Some miRNAs are also associated with the invasive and metastatic 
phenotype of breast cancer cell lines and have been identified in metastatic tumor tissues 
and lymph nodes (Dumont and Tisty, 2009).  
  Cumulating data have revealed that miRNAs exert their effects at multiple steps 
in the metastatic cascade by influencing cancer cell adherence, migration, invasion, 
motility, and angiogenesis (Dumont and Tisty, 2009). Recent expression profiling has 
identified breast cancer metastasis-associated miRNAs that are active players in breast 
cancer invasion and metastasis (Shi et al., 2010). MiRNA MiR-103/107 may directly 
bind the mRNA that codes Dicer therefore leading to the down-regulation of Dicer and 
causing extensive suppression of mature miRNAs (Martello et al., 2010). Overexpressing 
miR-103/107 in vitro enhanced cell invasion and migration and promoted metastasis in 
vivo (Martello et al., 2010).  Another miRNA believed to play an important role in breast 
cancer metastasis is miR-31 (Valastyan et al., 2009). Valastyan et al. (2009) 
overexpressed miR-31 in aggressive SUM-159 human breast cancer cells and reduced 
invasion by 20-fold and motility by 10-fold in vivo. The molecular mechanisms in which 
miRNAs become deregulated and affect the process of breast cancer metastasis is newly 
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emerging and holds promising insights into breast cancer pathogenesis.   
  MiR-155 is another well known miRNA overexpressed in many cancers (Jiang, et 
al., 2010). MiR-155 overexpression in breast cancer has been found to be correlated with 
poor prognosis. Jiang et al. (2010) identified ‘suppressor of cytokine signaling 1’ 
(SOCS1) as a novel target of miR-155 in breast cancer cells. SOCS1 is a tumor 
suppressor and when miR-155 is overexpressed in breast cancer cells, proliferation, 
colony formation and xenograft tumor growth is increased via the repression of SOCS1. 
  One of the best-characterized oncogenic miRNAs is miR-21 (Frankel et al., 2008, 
Iorio et al., 2005, Si et al., 2007, & Zhu et al., 2007). Inhibition of miR-21 was shown to 
increase apoptosis, inhibit breast cancer cell growth and survival in vitro and in vivo (Si 
et al., 2007). Frankel et al. (2008) and Zhu et al. (2007, 2008) have identified 
tropomyosin 1 (TPM1), maspin (SERPINB5) and the tumor suppressor gene 
programmed cell death-4 (PDCD4) as direct targets of miR-21 in breast cancer. These 
tumor suppressor genes, when down-regulated by miR-21 lead to increased proliferation, 
growth, migration and invasion. Huang et al. reported that HER2 initiates signaling that 
leads to miR-21 up-regulation, resulting in down-regulation of PDCD4 and therefore an 
increased ability of breast tumor cells to invade (Huang et al., 2009).  
  Members of the let-7 family of miRNAs are known to act as tumor suppressors 
(Kumar et al., 2008). Let-7 has been found to be frequently down-regulated in human 
cancer, leading to an up-regulation of the proto-oncogene RAS (Johnson et al., 2005). 
Let-7 also seems to be involved in the modulation of the cancer stem cell (CSC) 
phenotype. It has been reported that let-7 miRNAs are under-expressed in CSCs and 
TICs (Droge and Davey, 2008).   
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  MiRNA profiles are just as heterogeneous as breast cancer tumors themselves. 
MiRNA profiles have been correlated with pathological variables such as HER2+, ER+, 
or PR+ status, tumor stage, vascular invasion or proliferation indexes (Andorfer et al., 
2011). A recent analysis of 453 known miRNAs in 29 early-stage breast cancer tumors 
identified predicative signatures corresponding to ER+ (miR-342, miR-299, miR-217, 
miR-190, miR-135b and miR-218), PR+ (miR-520, miR-377, miR-527-518a, and miR-
520f-520c) and HER2+ (miR-520d, miR-181c, miR-302c, miR-376b, and miR-30e) 
status (Lowery et al., 2009). These subtype specific miRNA signatures will be of 
significant value to complement current methods of classification (Andorfer et al., 2011). 
The development of tailored breast cancer profiles that define a potential relation 
among circulating miRNAs, disease status, tumor subtype, response to therapy and risk 
of metastasis is a promising avenue that will help treat individual breast cancer patients 
more effectively. Although the progress made thus far is truly noteworthy, there is still 
much that needs to be investigated concerning the aberrant expression of miRNAs in 
breast cancer and the mechanisms by which they regulate breast cancer progression.  
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1.4 Cancer Stem Cells  
1.4.1. The Cancer Stem Cells (CSC) Hypothesis  
Cancer stem cells (CSCs) or “stem-like’ cells are a subset of cancer cells that are 
distinct from the other cells that form the bulk of a tumor. They possess stem cell 
properties, such as their abilities to self-perpetuate and to produce progenitor cells that 
undergo multi-lineage differentiation (Wicha et al., 2006). Putative CSCs are sometimes 
referred to as “tumor-initiating cells” (TICs). The idea that cancer might arise from a rare 
population of cells with stem cell properties was proposed many years ago (Wicha et al., 
2006). CSCs are capable of repopulating the tumor at all stages if not fully eliminated 
(Wicha et al., 2006).  It is believed that conventional chemotherapy kills the bulk of the 
tumor containing differentiated or differentiating cells, yet CSCs are resistant to such 
treatment and therefore can lead to recurrence of tumors (Al-Hajj, 2007 & Al-Hajj et al., 
2003). Therefore, CSCs have been hypothesized to be the source of cancer. The 
mechanisms leading to the metastatic dissemination of tumor cells is also thought to be 
due to this subpopulation of CSCs (Sleeman and Cremers, 2007). In order to develop 
new successful treatments for cancer it is important to elucidate the characteristics of 
CSCs and develop therapeutics that can target this tumorigenic CSC population.   
Multiple pathways and processes can give rise to CSCs. The molecular pathways 
that maintain the stem cell phenotype in stem cells are also active in numerous cancers. 
There are three hypotheses describing how CSCs may arise (Goldthwaite, 2011). First, 
CSCs may arise by mutation from normal stem cells. The similarity between CSCs and 
normal stem cells suggests that cancers may arise when some event produces a mutation 
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in a stem cell, causing it to become deregulated. Secondly, a progenitor cell may undergo 
two or more mutations that allow it to regain the properties of self-renewal and 
production of the heterogeneous lineages of cancer cells that comprise a tumor (Jamieson 
et al., 2004). Lastly, a fully differentiated cell may undergo several mutations that drive 
it back to a stem-like state. In all three circumstances, the resultant CSC has lost the 
ability to regulate its own cell division.  
1.4.2 CSCs and Breast Cancer  
Rare CSCs have been isolated from a number of human tumors, such as 
hematopoietic, brain, colon, pancreatic, prostate and breast cancers (Farnie and Clarke, 
2007). In breast cancer, previous studies have shown that CSC subgroups can be 
propagated in vitro from both primary tumors and established cell lines by culturing the 
cells as tumor spheres in suspension. Mammary stem cells are able to detach from the 
extracellular matrix and grow into spheroids and this property has been utilized in a 
technique that has been successfully used to obtain highly enriched and functional 
mammary stem cells from breast cancer cell lines (Dontu et al., 2003). One tumor sphere 
clonally originates from a single breast CSC and usually contains ~300 cells at various 
levels of differentiation (Dontu et al., 2003). In anchorage-independent conditions breast 
CSCs also exhibit a CD44+CD24-/low surface marker, also noted in situ, and can therefore 
be isolated by immunosorting based on the expression of these two markers (Dontu, 
2008). The development of agents that specifically kill breast CSCs has promising 
efficacy in the treatment of breast cancer. Gupta et al. (2009) looked at the effect of 
salinomycin, an antibacterial therapeutic drug, on treating breast CSCs. They found that 
salinomycin reduces the proportion of CSCs in mice by >100-fold relative to paclitaxel, 
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a commonly used breast cancer chemotherapeutic drug. Thus, analysis of CSCs is a 
promising avenue to further understand mechanisms underlying tumor cell migration, 
invasion and metastasis. Concordantly, identifying agents with specific toxicity for CSCs 
holds great promise in improving breast cancer treatment (Gupta et al., 2009). 
Identification of CSC-inducing or sustaining molecules may also unveil innovative 
therapeutic targets for eliminating CSCs (Tysen, 2010) and maintaining recurrence free 
survival.  
1.4.3 CSCs and miRNAs 
Investigating the important roles that miRNAs and CSCs play in various cancers 
is an innovative and popular area of research.  MiRNAs may play a role in the initial 
stages of breast cancer pathogenesis by regulating the phenotype of CSCs. Yu et al. 
(2007) looked at miRNA expression in breast TIC’s and found that miRNA let-7 was 
reduced in TICs and increased with cell differentiation. Lentivirus transfection of let-7 
into breast cancer TICs reduced proliferation, tumor sphere formation and the proportion 
of undifferentiated cells. It seemed that let-7 silenced two oncogenes: RAS and HMGA2. 
HMGA2 maintains pluripotency while RAS maintains self-renewal, so their 
overexpression in TICs gives them the stem-like phenotype of being able to self-renew 
and differentiate (Yu et al., 2007). Shimono et al. (2009) demonstrated that miR-200c 
repressed the expression of BMI1, a known regulator of stem cell self-renewal. 
Moreover, overexpression of miR-200c notably inhibited clonogenicity and tumor 
formation of breast CSCs in vitro and in vivo (Shimono et al., 2009).  These results 
suggest that miRNAs may play an important role in CSC activity. Hence, further 
investigation of miRNA expression profiles in CSCs will greatly facilitate the 
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development of novel therapeutic methods targeting the root of tumorigenesis and 
recurrence.  
1.5 Rationale  
 Preliminary data obtained by Dr. Mousumi Majumder in our laboratory by 
introducing the COX-2 gene into the non-metastatic MCF-7 (COX-2 negative, HER-2 
negative) and into the weakly metastatic SKBR-3 (COX-2 negative, HER-2 
overexpressing) human breast cancer cell lines, suggest that COX-2 expression induces 
and enhances sphere formation (Figure A2). After successful transfection of COX-2 
cDNA in MCF-7 and SKBR- 3 cells, stable integration of COX-2 was verified by DNA 
resequencing, quantitative-PCR (qPCR) and Western blotting. The resultant cell lines 
named MCF-7-COX-2 and SKBR-3-COX-2, when compared with mock (empty vector)-
transfected cells, showed: accelerated growth, migration and invasiveness in vitro and 
EMT (down-regulation of E-cadherin and up-regulation of vimentin, quantitated with 
qPCR); markedly increased TIC content, as indicated by tumor sphere (spheroid) 
forming ability of single cells in ultra–low attachment plates for successive generations 
(Figure 3); increased vascular mimicry on matrigel; up-regulation of the PGE2 receptor 
EP4 and angiogenic and lymphangiogenic factors VEGF- A, C and D (as quantitated by 
Western blots and qPCR). Treatment of the stable transfected cell lines with selective 
COX-2 inhibitor or EP4 antagonist abrogated most of the aggressive properties including 
migration, invasiveness, ability for vascular mimicry as well as TIC-associated tumor 
sphere forming ability, indicating the need for COX-2 and EP4 activity for these 
functions. 
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Through combined gene expression and miRNA micro array analysis, Dr. 
Majumder has subsequently identified two miRNAs (miR-526b and miR-655) that are 
up-regulated by stable transfection of the COX-2 gene in the human breast cancer cell 
line MCF-7 (Figure 3), in association with sphere formation and acquisition of an 
aggressive phenotype commonly associated with enhanced malignancy. These two COX-
2 up-regulated miRNAs were shown to down-regulate 14 target genes linked with tumor-
suppressor functions. Since miR-526b and miR-655 appear to be up-regulated by COX-2 
in an aggressive breast cancer cell line, they may be classified as oncogenic miRNAs that 
most likely target tumor-suppressor genes. We suggest that they may potentially 
contribute to the induction of the TIC phenotype in breast cancer. 
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Figure 3. Combined Gene Expression (Affymatrix Human Gene Array 1.0 ST) and 
miRNA (Affymatrix Genechip miRNAs Array) Micro Arrays. Differential gene 
(28870 genes covered) and microRNA (miRNA) arrays (848 human miRNA covered) 
where used to identify miRNAs and their target genes that where up- or down-regulated 
by introducing COX-2 into MCF-7 cells. We identified 26 genes that are down-regulated 
and 8 genes that are up-regulated in MCF7- COX-2 cells, with high statistical stringency. 
In the miRNA array only 2 miRNAs were up-regulated and 6 were down-regulated. In 
combined gene and miRNA data analysis we identified two miRNAs that are up-
regulated (≥1.5 fold) in MCF7-COX-2 cells that down regulate 14 genes, (≤1.5 fold), 
including TP53, CDK6, INSIG2, and NDRG1 among others (Majumder M et al., 2012). 
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1.6 Hypothesis and Objectives 
Based on the previously summarized results, the hypothesis of the present study 
is that the COX-2 up-regulated miRNA, miR-655, plays an important role in COX-2 and 
EP4 mediated induction of the TIC phenotype and the progression of human breast 
cancer. The overall objective will be to examine the regulatory role of COX-2 on the 
expression of miR-655 (Figure 4) and define the functional role that this miRNA has on 
the induction of TIC associated properties in human breast cancer cell lines. 
The proposed hypothesis will be tested through the following objectives: 
Use MCF-7, MCF-7-COX-2, SKBR-3 and SKBR-3-COX-2 cell lines: 
1.  a) To examine the role of COX-2 in breast cancer progression by performing 
functional assays, including transwell migration and invasion assays and the tumorsphere 
formation assay.  
b) To validate micro array data by quantifying expression of miR-655.  
2. To determine if the expression of miR-655 is dependent on COX-2 or EP4 activity. 
This will be determined by blocking COX-2 (with NS398) or EP4 activity (with ONO-
AE3-208) and then measuring changes in miRNA expression. 
3. To determine the effect of expressing miR-655 (in non-expressing breast cancer cell 
lines) on COX-2 expression, breast cancer cell migration, invasion and proliferation.  
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Figure 4. Proposed correlation of cyclooxygenase-2 (COX-2) expression and microRNA 
expression (miR-655) in the four COX-2 disparate cell lines.  
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CHAPTER TWO: EXPERIMENTAL PROCEDURES 
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2.1 Cell Lines and Culture 
The MCF-7 human breast cancer cell line is low COX-2 expressing, estrogen 
receptor (ER) positive HER-2 negative and is non-metastatic in immunodeficient mice. 
MCF-7 cells were purchased from American Type Culture Collection (ATCC) 
(Rockville, MD) and were grown as a monolayer in Minimum Essential Medium Eagle 
(MEME) (ATCC, Rockville, MD) supplemented with 8% fetal bovine serum (FBS), 
100U/ml penicillin, and 100ug/ml streptomycin in a humidified incubator with 5% CO2 
at 37°C. The weakly metastatic SKBR-3 human breast cancer cell line, also purchased 
from ATCC, does not express COX-2 and over-expresses HER-2. SKBR-3 cells were 
maintained as above, however they were grown in McCoy’s 5A Modified Medium with 
L-glutamine.  
In order to stably overexpress COX-2 in MCF-7 and SKBR-3 cells, Dr. 
Majumder in our lab transfected COX-2 cDNA into MCF-7 and SKBR-3 cell lines. 
Stable integration of COX-2 was verified by resequencing, quantitative real-time PCR 
and Western blots. The resultant cell lines named MCF-7-COX-2 and SKBR-3-COX-2, 
exhibited an increased aggressive phenotype as predicted with high COX-2 expression 
(see p.26 for details). MCF-7-COX-2 cells were maintained similar to MCF-7 cells and 
SKBR-3-COX-2 cells were maintained similar to SKBR-3 cells, however Geneticin® 
(Invitrogen, GIBCO, ON) was added to the media of COX-2 overexpressing cell lines at 
500µg/ml to maintain selective pressure for the transfected cells.  
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2.2 Quantitative Real-time Polymerase Chain Reaction (PCR) 
2.2.1 COX-2 mRNA Expression 
For RNA extraction and complementary DNA (cDNA) synthesis, cells were 
grown to 80-90% confluence, trypsinized and collected as cell pellets. Total RNA was 
extracted using the miRNeasy Minikit (Qiagen, MD) following the manufacture’s 
instructions. The total RNA was quantified with a spectrophotometer (NanoDrop 2000, 
Thermo Scientific, IL).  Synthesis of cDNA from the RNA was performed using the 
High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, CA) with 2µg of 
RNA per 20µl volume reaction, using a thermo cycler (C2000TM, Bio Rad). Quantitative 
real-time PCR was performed in single micro capillary tubes on a Rotor Gene 3000 
(Corbett Research, SF) with TaqMan® Universal PCR Master Mix (Applied Biosystems, 
CA) for both the housekeeping gene (TaqMan® Gene Expression Assay GAPDH probe, 
for monolayer cells, or TaqMan® Gene Expression Assay β-Actin probe, for tumor 
spheres), and the target gene expression (TaqMan® Gene Expression Assay COX-2 
probe). Each quantitative real-time PCR reaction was prepared to a volume of 20µl, 
including 1 µl of the appropriate TaqMan probe, and 2µl of the cDNA. The quantitative 
real-time PCR profile was 95°C for 15 seconds of denaturation and 58°C for 1 minute of 
anneal-extension for 40 cycles.  
 
2.2.2 MiR-655 Expression 
Quantitative real-time PCR for miR-655 (hsa-miR-655) expression was 
performed following the previously described protocol (2.2.1) with the following 
modifications. Total miRNA was extracted from the cells using the miRNeasy Minikit 
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and the RNeasy MiniElute Cleanup kit (Qiagen, MD) following the manufacturer’s 
instructions. Complementary DNA was synthesized from the extracted miRNA using 
specific stem-loop primers for the miRNA under investigation (TaqMan® MicroRNA 
Assays, miR-655 primer) and the endogenous housekeeping miRNA (TaqMan® 
MicroRNA Assays, RNU 44 primer) and the TaqMan® MicroRNA Reverse 
Transcription Kit (Applied Biosystems, CA) following the manufacture’s protocol. 
Quantitative real-time PCR was performed in single micro capillary tubes on a Rotor 
Gene 3000 (Corbett Research, SF) with TaqMan® Universal PCR Master Mix, No 
AmpErase UNG (Applied Biosystems, CA) for both the housekeeping miRNA 
(TaqMan® MicroRNA Assays, RNU 44 probe) and the target miRNA (TaqMan® 
MicroRNA Assays, miR-655 probe) as recommended by the manufacturer.  
 
2.2.3 Roles of COX-2 and EP4 Activity on the Expression of miR-655 
MCF-7-COX-2 and SKBR-3-COX-2 cells were plated at 1 million cells/well in 
6-well plates and incubated overnight in complete MEME and McCoy’s 5A respectively. 
The next day, cells were incubated in serum-free medium for 2 hours and then treatments 
of 20µM selective COX-2 inhibitor NS-398, 2µM EP4 antagonist ONO-AE3-208, or 
control (0.02% DMSO) were added. After 24 hours of treatment, cDNA was synthesized 
from miRNA extracted from the cells. Quantitative real-time PCR for miR-655 
expression was performed following the previously described protocol (2.2.2).  
2.2.4 Quantitative Real-time PCR for mRNA or miRNA Expression 
Quantitative real-time PCR reactions were performed in triplicate. The delta-delta 
Ct method was employed for quantification of the fold change in mRNA or miRNA 
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expression for the samples under investigation. Each sample was repeated in triplicate in 
each run and the mean Ct (mean cycle threshold) value was calculated for each sample. 
The Ct value of the endogenous housekeeping gene (either GAPDH/ β-actin for mRNA 
quantification, or RNU44 for miRNA quantification) was subtracted from the mean Ct 
value of the sample under investigation to determine the resulting delta Ct value (ΔCt). 
The ΔCt value of the reference sample was then subtracted from the ΔCt of the sample 
under investigation to produce the delta-delta Ct value (ΔΔCt). The fold difference was 
finally determined (2-ΔΔCt).  
  
2.3 Western Blot Analysis: COX-2 Protein Expression  
Cells were grown to 80-90% confluence in 75cm2 flasks (BD falcon, CA). For 
analysis of total cell lysates, cells were rinsed in ice cold PBS and lysed in M-PER 
Mammalian Protein Extraction Reagent (Thermo Scientific, IL) supplemented with 
HALT protease inhibitor cocktail (Thermo Scientific, IL). After five minutes of shaking 
on ice, cells were scraped from tissue culture dishes and transferred to 1.5 ml Eppendorf 
tubes. For tumorspheres (described below in 2.6), cells were pelleted in 1.5 ml 
Eppendorf tubes, rinsed with ice cold PBS and re-suspended in the M-PER/HALT 
solution and left to shake on ice for five minutes. Lysates were sonicated (eight pulses at 
level four) and then centrifuged at 13 000 RCF for 20 minutes at 4°C, to remove cell 
debris. The supernatants were collected and protein concentration was quantified in 
triplicate using the Pierce® BCA Protein Assay Kit (Thermo Scientific, IL) following 
the manufacturer’s protocol. Fifteen micrograms of total protein from the cell lysate was 
run per well on a 1.5 mm 10% SDS-PAGE gel (polyacrylamide gel electrophoresis) at 
	  	  
36	  
90V (voltage) for one and a half hours. The proteins were then transferred to an 
Immobilon-FL PVDF membrane at 5V for 3 hours (semi-dry transfer). After the transfer 
the membrane was blocked for one hour in a blocking buffer consisting of TBST (20mM 
tris-base, 0.14M NaCl, 0.01% Tween, pH 7.4) and 2% albumin from bovine serum 
(BSA) (Sigma-Aldrich®, MO). The membrane was then incubated in a mixture of 
primary antibodies; for cells grow as a monolayer: mouse monoclonal GAPDH (1:5000) 
(Millipore, MA) and goat polyclonal COX-2 (1:1000) (Abcam, MA), and for cells grown 
as tumorspheres: mouse monoclonal β-actin (1: 5000) (Santa Cruz Biotechnology, CA) 
and goat polyclonal COX-2 (1:1000) (Abcam, MA), diluted in a solution of TBST (pH 
7.4) with 2% BSA overnight at 4°C. After being washed in TBST (pH 7.4) three times 
15 minutes each, the membrane was probed with a mixture of a donkey anti-goat 
(1:5000) and donkey anti-mouse (1:10000) IRDye polyclonal secondary antibodies (LI-
COR, NE) diluted in a solution of TBST (pH 7.4) with 2% BSA for one hour in the dark. 
Finally, the membrane was washed three times 15 minutes each in TBST (pH 7.4) before 
scanning on an Odyssey infrared imaging system (LI-COR, NE).  
  
2.4 Transwell Assays 
2.4.1 Cellular Migration 
Cellular migration (chemokinesis) was measured using 24-well cell culture 
chambers (BD Biosciences, CA) fitted with multiporous (8 µm pore size) polycarbonate 
membranes (BD Biosciences, CA) (Timoshenko et al., 2006). The uncoated upper 
chamber (insert) with membrane was filled with 300 µl of serum-starved cells in 
suspension (2 x105 cells/ml) in appropriate media, while the lower chamber (wells) 
	  	  
37	  
contained 700 µl of the same cell free media with no FBS or 2% FBS as indicated. Plates 
were placed in a humidified CO2 incubator for 24 hours at 37°C. It has been observed in 
our lab that the peak point of migration occurs at 24 hours (Timoshenko et al., 2003). 
The inserts were then removed and the upper surface of the membranes were gently 
wiped with cotton swabs to remove the non-migratory cells. The membranes were then 
fixed with methanol and stained with eosin and thiasine and then mounted onto slides. 
The number of cells appearing on the undersurface of the polycarbonate membranes 
were counted visually using a light microscope (LEICA DFC 295). For each sample, the 
cells on the entire membrane were counted and a mean value for each sample was 
calculated.  
 
2.4.2 Cellular Invasion 
Cellular invasion is similar to cellular migration; however, it requires a cell to 
migrate through an extracellular matrix (ECM) or basement membrane (BME) barrier by 
enzymatic degradation. Therefore, the multiporous (8 µm pore size) polycarbonate 
membranes (BD Biosciences, CA) were coated with Matrigel (BD Biosciences, CA), a 
gelatinous protein mixture secreted by Engelbreth-Holm-Swarm (EHS) mouse sarcoma 
cells that resembles the complex extracellular environment found in many tissues (Zhou 
et al., 2010). Growth Factor Reduced (GFR) Matrigel (BD Biosciences, CA) was thawed 
overnight at 4°C, diluted with cold media (1:100) and placed on the transwell 
membranes to solidify. The Matrigel coated upper chamber membranes were then filled 
with 300 µl of cell suspension (2 x105 cells/ml) in appropriate media, while the lower 
chamber (wells) were filled with 700 µl of cell free media with either no FBS or 2% FBS 
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as indicated. The cells were allowed to invade for 48 hours in a humidified CO2 
incubator at 37°C. It has been observed in our lab that the peak point of invasion occurs 
at 48 hours (Majumder et al., 2012). The membranes were then fixed, stained and 
quantified as previously described (2.4.2). 
 
2.5 Nucleotransfection with miR-655 Overexpression Plasmid 
The MicroRNA Expression Plasmids (purchased from OriGene, MD) were 
synthesized by cloning the amplified precursor microRNA into OriGene’s pCMV6-Mir 
vector (Appendix figure 1). The expression of the miRNA is driven by the CMV 
promoter and with the human growth factor 1 poly(A) tailing signal (OriGene, MD). 
Confirmation of transfection and miR-655 over expression was done microscopically by 
validating expression of the GFP reporter and by performing quantitative real-time PCR 
(2.2.2). 
MCF-7 and SKBR-3 cells were grown to 80-90% confluence in 75cm2 flasks 
(BD Falcon, CA) and then gently harvested from the substrate. The harvested cells, at a 
concentration of 2 x106 cells/ml, were distributed into certified cuvettes and transfected 
with 2ug of either the pCMV-MIR mock vector (control empty vector) or the pCMV-
MIR miR-655 Expression Plasmid (Origene, MD) using the Amaxa Cell Line 
Nucleofactor Kit V (Lonza, MO) and the E-009 or P-020 program for MCF-7 cells or 
SKBR-3 cells respectively according to the manufacturer’s protocol. After nucleofection, 
cells were placed in an antibiotic free medium and incubated at 37°C, 5% CO2 for 48 
hours. MCF-7 and SKBR-3 cell lines transiently transfected with the pCMV-MIR mock 
(empty) vector are referred to as MCF-7-mock and SKBR-3 mock respectively. Likewise, 
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MCF-7 and SKBR-3 cell lines transiently transfected with the pCMV-MIR miR-655 
Expression Plasmid are referred to as MCF-7-655 and SKBR-3-655 respectively.  
2.6 Tumorsphere Formation Assay 
Sphere formation is an in vitro assay, which analyzes the ability of cells to self-
renew and form tumorspheres, which is indicative of the cancer stem cell (CSC) 
phenotype. Primary tumorspheres were generated from cultured cells by seeding on 6-
well ultra-low attachment plates (Corning, MA) at 2x104cells/ml in HuMEC media 
(GIBCO, ON) supplemented with epidermal growth factor (EGF), basic fibroblast 
growth factor basic (bFGF) and B27 (Invitrogen, ON). Tumorspheres were grown from 
MCF-7, MCF-7-COX-2, SKBR-3, and SKBR-3-COX-2 human breast cancer cell lines 
for 10 -14 days, or until tumorspheres reached a size of at least 60µm in diameter. The 
tumorspheres were then harvested and used for either quantitative real time PCR to 
quantify COX-2 mRNA expression (2.2.1) and miR-655 expression (2.2.2), or for 
Western blot analysis for COX-2 protein expression (2.3).  
 
2.7 Cell Proliferation ELISA, BrdU Assay 
To examine whether miR-655 stimulates MCF-7 and SKBR-3  cellular 
proliferation, transiently transfected cells (2.5) were used in a BrdU assay 48 hours post-
transfection. MCF-7, MCF-7-mock, MCF-7-655, SKBR-3, SKBR-3-mock, and SKBR-
3-655 cells were harvested and seeded onto 96-well tissue-culture microplates (BD 
Biosciences, CA) at 1x104cells/ml and incubated at 37°C, 5% CO2 for 24 hours. After 
incubation, the quantification of cell proliferation was performed by the measurement of 
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BrdU incorporation in newly synthesized cellular DNA using the Cell Proliferation 
ELISA, BrdU (colorimetric) Kit purchased from Roche, following the manufacture’s 
protocol.  Proliferating cells were labeled by the addition of BrdU labeling solution for 
six hours. During this labeling period, BrdU was incorporated into the DNA of dividing 
cells. After removing the labeling medium, the cells were fixed, and the DNA was 
denatured in one step by adding FixDenat. After removing FixDenat, the anti-BrdU-POD 
antibody was added, which becomes bound to the BrdU incorporated into the newly 
synthesized cellular DNA. The immune complexes were detected by the subsequent 
substrate reaction. The reaction product was measured with an ELISA plate reader 
(Infinite M200, TECAN) at a wavelength of 370 nm (reference wavelength 492 nm).  
2.8 Statistical Analysis 
 Statistical calculations were performed using GraphPad Prism Software Version 
5 (GraphPad Software, La Jolla, CA). Quantitative real-time PCR results for COX-2 
mRNA and miR-655 expression in MCF-7, MCF-7-COX-2, SKBR-3, and SKBR-3-
COX-2 cells grown as a monolayer or tumorsphere, were tested by Student’s t-test. All 
other data were analyzed with a one-way ANOVA followed by a post-hoc TUKEY’s 
test. A p-value of less than 0.05 was considered statistically significant as indicated in 
each figure.  
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3.1 Introduction of COX-2 Increases the Migration and Invasion of MCF-7 and 
SKBR-3 Human Breast Cancer Cell Lines 
3.1.1 Verification of COX-2 Expression 
Our laboratory has shown that overexpression of COX-2 in human, as well as 
murine breast cancer cells, promotes tumor progression and metastasis by multiple 
mechanisms. These include host immune cell inactivation (Lala et al., 1986), as well as 
stimulation of cancer cell migration, invasion, tumor-associated angiogenesis (Rozic et 
al., 2001) and lymphangiogenesis (Timoshenko et al., 2006), which support blood-borne 
and lymph-borne metastasis. Recently, by stable transfection of COX-2 cDNA into 
COX-2 negative non-metastatic MCF-7 and COX-2 negative HER-2 positive weakly 
metastatic SKBR-3 human breast cancer cell lines, it was further shown that COX-2 
induces all the phenotypic properties of aggressive breast cancer, including induction of 
the CSC phenotype (Majumder et al., 2012). These cell lines were respectively named 
MCF-7-COX-2 and SKBR-3-COX-2. Correspondingly, empty vector transfected cells 
were named MCF-7-mock and SKBR-3-mock.  
 Overexpression of COX-2 in breast cancer cell lines was tested with RT-PCR and 
quantitative real-time PCR to determine COX-2 mRNA expression and Western blot to 
analyze COX-2 protein expression (Figure 5 & Figure 6). Lysates and RNA from 
cultured MCF-7-mock, MCF-7-COX-2 (Figure 5 (A)), SKBR-3-mock, and SKBR-3-
COX-2 (Figure 6 (A)) cells were assayed by RT-PCR and Western blot respectively. The 
levels of GAPDH mRNA and protein were measured and used as the internal 
normalization control. Real-time PCR analysis determined that COX-2 mRNA  
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Figure 5. Expression of COX-2 mRNA and protein in MCF-7-mock and MCF-7-
COX-2 human breast cancer cells as detected by RT-PCR, Western blot, and 
quantitative real-time PCR. (A) Lysates and RNA from cultured MCF-7-mock and 
MCF-7-COX-2 cells were assayed by RT-PCR and Western blot respectively. GAPDH 
(housekeeping gene) was used as an internal control. (B) COX-2 mRNA expression by 
quantitative real-time PCR (with Taqman probes) is presented as relative fold change (2-
ΔΔCT method). Relative fold changes were normalized to internal control GAPDH. MCF-
7 results were plotted as a value of one. MCF-7-COX-2 was observed to express COX-2 
mRNA at ~300 fold higher level, as compared to MCF-7-mock cells. The data are 
represented as mean +/- standard deviation (SD) for three independent experiments. (*) 
indicates significant difference (p<0.05). 
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Figure 6. Expression of COX-2 mRNA and protein in SKBR-3-mock and SKBR-3-
COX-2 human breast cancer cells as detected by RT-PCR, Western blot, and 
quantitative real-time PCR. (A) Lysates and RNA from cultured SKBR-3-mock and 
SKBR-3-COX-2 cells were assayed by RT-PCR and Western blot respectively. GAPDH 
(housekeeping gene) was used as an internal control. (B) COX-2 mRNA expression by 
quantitative real-time PCR (with Taqman probes) is presented as relative fold change (2-
ΔΔCT method). Relative fold changes were normalized to internal control GAPDH. 
SKBR-3 results were plotted as a value of one. SKBR-3-COX-2 was observed to express 
COX-2 mRNA at ~500 fold higher level as compared to SKBR-3-mock cells. The data 
are represented as mean +/- standard deviation (SD) for three independent experiments. 
(*) indicates significant difference (p<0.05). 	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expression levels in the cells were ~300 fold higher compared to MCF-7-mock cells 
(Figure 5 (B)). There was ~500 fold change in SKBR-3-COX-2 cells compared to 
SKBR-3-mock cells (Figure 6 (B)).  
3.1.2 Effects of COX-2 Overexpression on Cellular Migration and Invasion  
Functional assays were performed for migration (across microporous membranes 
inserted in transwells) and invasion (using transwells containing matrigel-coated 
microporous membranes) using MCF-7, MCF-7-COX-2, SKBR-3 and SKBR-3-COX-2 
cell lines. Previous studies in our laboratory have shown that the mock transfected and 
parental cells lines show no difference in COX-2 expression and therefore the parental 
cell lines were used throughout these experiments as the negative control (Majumder et 
al., 2012).  For migration (Figure 7), cells were separately plated on the top chambers of 
transwell migration inserts and allowed to migrate for 24 hours. The bottom chambers 
contained serum free medium (SFM) or medium with 2% FBS as indicated. Three 
independent experiments with each cell line were carried out in triplicate. The cells on 
each membrane were counted manually. Overexpressing COX-2 in MCF-7 (Figure 7 
(A)) breast cancer cell lines significantly increased the ability of these cells to migrate, 
supporting the idea that COX-2 stimulates migration of human breast cancer cells. In the 
case of the SKBR-3 cells, the differences become significant when migration was done 
in 2% FBS (Figure 7 (B). Representative images (Figure 7 (C) and (D)) are shown.   
Cellular invasion is defined by the ability of a cell to migrate through the ECM or 
basement membrane barrier by enzymatic degradation. Therefore, for the invasion assay 
(Figure 8), cell lines were plated on the top chamber of transwell inserts coated with  
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Figure 7. Introduction of COX-2 increases migration of MCF-7 and SKBR-3 
human breast cancer cells. MCF-7 & MCF-7-COX-2 (A & C), and SKBR-3 & SKBR-
3-COX-2 (B & D) cell lines were plated on the top chambers of transwell migration 
inserts and allowed to migrate for 24 hours. The bottom chambers contained serum free 
medium (SFM) or medium with 2% FBS as indicated. Three independent experiments 
with each cell line were carried out in triplicate. The cells on each membrane were 
counted manually. Overexpressing COX-2 in MCF-7 (A) and SKBR-3 (B) breast cancer 
cell lines increased the ability of these cells to migrate, supporting the idea that COX-2 
stimulates migration of human breast cancer cells. The data are represented as mean +/- 
standard deviation (SD) for three independent experiments. Different superscripts 
indicate statistically significant differences, while shared superscripts indicate no 
significant difference (p<0.01). (C & D) Images of the migration transwell membranes 
for each cell line with 2% FBS (40X), showing the morphology of the migratory cells.  	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Matrigel, a solubilized basement membrane preparation, and allowed to invade for 48 
hours. The bottom chambers contained SFM or medium with 2% FBS as indicated. 
Three independent experiments with each cell line were carried out in triplicate. The 
cells on each membrane were counted manually (Figure 8). In particular, MCF-7-COX-2 
cells showed a significant increase in ability to invade in both the SFM and 2% FBS 
treated groups, supporting the idea that COX-2 stimulates cellular invasion in human 
breast cancer. 
Based on these results, it can be concluded that COX-2 plays an important role in 
promoting the aggressive breast cancer phenotype, indicated by the increased ability of 
the COX-2 overexpressing cells to migrate and invade.  
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Figure 8. Introduction of COX-2 increases invasion of MCF-7 and SKBR-3 human 
breast cancer cells. MCF-7 & MCF-7-COX-2 (A), and SKBR-3 & SKBR-3-COX-2 (B) 
cell lines were plated on the top chamber of transwell inserts coated with Matrigel and 
allowed to invade for 48 hours. The bottom chambers contained serum free medium 
(SFM) or medium with 2% FBS as indicated. Three independent experiments with each 
cell line were carried out in triplicate. The cells on each membrane were counted 
manually. Overexpressing COX-2 in MCF-7 (A) breast cancer cell lines increased the 
ability of these cells to invade, supporting the idea that COX-2 stimulates cellular 
invasion in human breast cancer. A trend was seen in the SKBR-3 cell lines. The data are 
represented as mean +/- standard deviation (SD) of three independent experiments. 
Different superscripts indicate statistically significant differences, while shared 
superscripts indicate no significant difference (p<0.01).  	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3.2 MiR-655 Expression in MCF-7, MCF-7-COX-2, SKBR-3 and SKBR-3-COX-2 
Human Breast Cancer Cell Lines 
Through combined gene expression and miRNA microarray analysis our 
laboratory has recently identified two miRNAs, miR-526b and miR-655, that are up-
regulated in MCF-7-COX-2 cells and associated with a down-regulation of 14 target 
genes linked with tumor-suppressor functions. This thesis focused on the specific role of 
miR-655 in relation to COX-2 expression and human breast cancer progression. The data 
for miR-655 expression was validated in the MCF-7, MCF-7-COX-2, SKBR-3 and 
SKBR-3-COX-2 cell lines by quantification of miR-655 expression with Applied 
Biosystems Taqman miRNA expression assay (Figure 9).  Overexpressing COX-2 in 
MCF-7 (Figure 9 (A)) and SKBR-3 (Figure 9 (B)) cell lines significantly increased the 
expression of miR-655. MCF-7-COX-2 showed ~18,000 fold increase in miR-655 
expression relative to the MCF-7 parental cell lines. SKBR-3-COX-2 showed ~ 10 fold 
increase in miR-655 expression relative to the SKBR-3 parental cell line. To conclude, it 
appears that miR-655 expression is increased in response to COX-2 up-regulation. 
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Figure 9. Expression levels of miR-655 in MCF-7, MCF-7-COX-2, SKBR-3, and 
SKBR-3-COX-2 human breast cancer cell lines. Analysis of miR-655 expression by 
quantitative real-time PCR (with Taqman probes). Results presented in relative fold 
change (2-ΔΔCT method). Relative fold changes were normalized to internal control 
RNU44. Overexpressing COX-2 in MCF-7 (A) and SKBR-3 (B) cell lines significantly 
increased the expression of miR-655. The data are represented as mean +/- standard 
deviation (SD) for three independent experiments. (*) indicates significant difference 
(p<0.05) relative to parental cell line. Parental cell lines were given a value of 1.  
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3.3 Treatment with COX-2 Inhibitor and EP4 Antagonist Decreases the Expression 
of miR-655 in COX-2 Overexpressing Cell lines 
Previous work in our lab has shown that selective COX-2 inhibitors reduced 
tumor cell migration and invasion in vitro (Rozic et al., 2001). It was further shown that 
COX-2 mediated promotion of migration was at least in part mediated by endogenous 
PGE2, acting primarily via the EP4 receptor (Timoshenko et al., 2003).  Looking at the 
effects of blocking COX-2 was performed in order to test the casual relationship between 
COX-2 activity and miR-655 expression in the COX-2 expressing breast cancer cell lines. 
Blocking EP4 activity was performed to determine if miR-655 up-regulation is 
dependent on this particular receptor. The working hypothesis tested was that blocking 
COX-2 or EP4 activity in the high COX-2 expressing cell lines would reduce the level of 
miR-655 expression.  
To test this hypothesis, MCF-7-COX-2 and SKBR-3-COX-2 cells were plated at 
1 million cells/well in 6-well plates and incubated overnight in complete DMEM or 
McCoy’s respectively. The next day, cells were incubated in serum-free medium for 2 
hours, and then treatments of 20µM selective COX-2 inhibitor NS-398, 2µM EP4 
antagonist ONO-AE3-208, or control (0.02% DMSO) were added. After 24 hours of 
treatment, cDNA was synthesized using specific primers from miRNA extracted from 
the cells. Quantitative real-time PCR was performed to analyze the expression levels of 
miR-655.  
In both MCF-7-COX-2 and SKBR-3-COX-2 human breast cancer cell lines, 
treatment with the COX-2 inhibitor NS-398 and the EP4 antagonist ONO-AE3-208 
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significantly decreased the expression of miR-655 (Figure 10).  This indicates that the 
expression of miR-655 in human breast cancer cell lines is dependent on both COX-2 
and EP4 activity.  
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Figure 10. MiR-655 expression in response to COX-2 inhibitor and EP4 antagonist 
in MCF-7-COX-2 (A) and SKBR-3-COX-2 (B) human breast cancer cell lines. 
MCF-7-COX-2 (A) and SKBR-3-COX-2 (B) cells were treated with either 20µM 
selective COX-2 inhibitor (NS-398), 2µM EP4 antagonist (ONO-AE3-208), or vehicle 
(0.02% DMSO) for 24 hours. After treatment, cDNA was synthesized from miRNA 
extracted from the cells using specific Taqman primers. Analysis of miR-655 expression 
was performed by quantitative real-time PCR (with Taqman probes). Results presented 
in relative fold change (2-ΔΔCT method). Relative fold changes were normalized to 
internal control RNU44. In both MCF-7-COX-2 (A) and SKBR-3-COX-2 (B) human 
breast cancer cell lines, treatment with the COX-2 inhibitor NS-398 and the EP4 
antagonist ONO-AE3-208 significantly decreased the expression of miR-655. This 
indicates that the expression of miR-655 in human breast cancer cell lines is dependent 
on both COX-2 and EP4 activity. The data are represented as mean +/- standard 
deviation (SD) for three independent experiments. (*) indicates significant difference 
(p<0.05) and (**) indicates significant difference (p<0.001) relative to the cell line 
treated with vehicle (0.02% DMSO).  
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3.4 COX-2 and miR-655 Expression in Tumorspheres in Comparison to Cells 
Grown as a Monolayer 
3.4.1. Cells Derived from Tumorspheres Have a Higher COX-2 Expression in 
Comparison to Cells Grown as a Monolayer 
The tumorsphere formation assay is an in vitro correlate of the CSC phenotype by 
analyzing the ability of cancer stem-like cells to self-renew. MCF-7, MCF-7-COX-2, 
SKBR-3, and SKBR-3-COX-2 cells were grown in 6-well low attachment plates and 
allowed to form tumorsphere (as detailed in the methodology 2.6) for 7-14 days or until 
tumorspheres reached a size of at least 60µm in diameter (Figure 11). The tumorspheres 
in each well were pooled and harvested for either quantitative real-time PCR (Figure 11 
(B)) or Western blot analysis (Figure 11 (C)). Expression levels of β-actin were used as 
an internal control. MCF-7 and MCF-7-COX-2 cells formed more spherical 
tumorspheres in comparison to SKBR-3 and SKBR-3-COX-2 cells, which formed 
irregular spheres (Figure 11 (A)). COX-2 mRNA expression was significantly increased 
in the cells grown as tumorspheres in comparison to the same cells grown as a monolayer 
(Figure 11 (B)). MCF-7 tumorspheres exhibited a 14 fold increase in COX-2 mRNA 
expression, while MCF-7-COX-2 tumorspheres exhibited a 6 fold increase in COX-2 
mRNA expression relative to cells grown as a monolayer (Figure 11 (B)). SKBR-3 
tumorspheres exhibited a 6 fold increase, while SKBR-3-COX-2 exhibited a 5 fold 
increase in COX-2 mRNA expression relative to cells grown as a monolayer (Figure 11 
(B)).  Analysis of COX-2 protein expression by Western blot revealed that COX-2 
protein is also up-regulated in the cell lines grown as tumorspheres in comparison to 
cells grown as a monolayer (Figure 11 (C)).   
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To conclude, COX-2 expression is significantly increased at the mRNA and 
protein levels in cell lines grown as tumorspheres relative to the same cell lines grown in 
monolayer. COX-2 therefore appears to play an important role in promoting and 
maintaining the CSC phenotype in vitro.  
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Figure 11. Cells derived from tumorspheres have a higher COX-2 expression in 
comparison to cells grown as a monolayer. Cells were grown in 6-well low attachment 
plates at 2x104cells/ml and allowed to form tumorspheres (in vitro correlate of CSC 
growth) for 7-14 days or until tumorspheres reached a size of at least 60µm in diameter. 
The tumorspheres in each well were pooled and harvested for either quantitative real-
time PCR (B) or Western blot analysis (C). (A) Images of MCF-7, SKBR-3 and SKBR-
3-COX-2 tumorspheres at 10 days and MCF-COX-2 tumorspheres at 7 days. MCF-7 and 
MCF-7-COX-2 cells formed more spherical tumorspheres in comparison to SKBR-3 and 
SKBR-3-COX-2 cells, which formed irregular spheres. (B) Analysis of COX-2 mRNA 
expression by quantitative real-time PCR (with Taqman probes). Results presented in 
relative fold change (2-ΔΔCT method). Relative fold changes were normalized to internal 
control β-actin. COX-2 mRNA expression was significantly increased in the cells grown 
as tumorspheres in comparison to the same cells grown as a monolayer. The data are 
represented as mean +/- standard deviation (SD) for three independent experiments. (*) 
indicates significant difference (p<0.05) relative to the same cell line grown as a 
monolayer. (C) Analysis of COX-2 protein expression by Western blot. β-actin was used 
as a loading control. COX-2 protein is observed to be up-regulated in MCF-7 and MCF-
7-COX-2 cell lines grown as tumorspheres (Tumor) in comparison to cells grown as a 
monolayer (Mono). 	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3.4.2 Cells Derived from Tumorspheres have a Higher miR-655 Expression in 
Comparison to Cells Grown as a Monolayer	  
To determine the expression of miR-655 in cells grown as tumorspheres, MCF-7, 
MCF-7-COX-2, SKBR-3, and SKBR-3-COX-2 cells were grown in 6-well low 
attachment plates and allowed to form tumorspheres for 7-14 days or until tumorspheres 
reached a size of at least 60µm in diameter (Figure 12). The tumorspheres in each well 
were pooled and harvested for quantitative real-time PCR for miR-655 quantification. 
MiR-655 expression was significantly increased in the cells grown as tumorspheres in 
comparison to the same cells grown as a monolayer (Figure 12). MCF-7 tumorspheres 
exhibited ~ 100,000 fold increase in miR-655 expression, while MCF-7-COX-2 
tumorspheres exhibited ~1000 fold increase in miR-655 expression relative to cells 
grown as a monolayer (Figure 12 (A)). SKBR-3 tumorspheres exhibited a 5-fold increase 
in miR-655 expression relative to cells grown as a monolayer (Figure 12 (B)).  
To conclude, miR-655 expression is significantly increased in MCF-7, MCF-7-
COX-2, and SKBR-3 cell lines grown as tumorspheres relative to the same cell lines 
grown in monolayer. MiR-655 therefore appears to play an important role in promoting 
and tumorsphere formation in vitro.  
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Figure 12.  Tumorspheres grown from MCF-7, MCF-7-COX-2 and SKBR-3 cells 
exhibit overexpression of miR-655.  Cells were grown in 6-well low attachment plates 
at 2x104cells/ml and allowed to form tumorspheres for 7-14 days or until tumorspheres 
reached a size of at least 60µm in diameter. The tumorspheres in each well were pooled 
and harvested for quantitative real-time PCR analysis of miR-655 expression (with 
Taqman probes). Results presented in relative fold change (2-ΔΔCT method). Relative fold 
change was normalized to internal control RNU44. MCF-7 and MCF-7-COX-2 cells (A) 
and SKBR-3 (B) cells grown as tumorspheres showed a significantly higher miR-655 
expression compared to the same cells grown as a monolayer. The data are represented 
as mean +/- standard deviation (SD) for three independent experiments. (*) indicates 
significant difference (p<0.05) and (**) indicates significant difference (p<0.001) 
relative to cells grown as a monolayer.  
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3.5 Introduction of miR-655 Increases the Migration and Invasion of MCF-7 and 
SKBR-3 Breast Cancer Cell Lines 
3.5.1 Introduction of miR-655 into MCF-7 and SKBR-3 Human Breast Cancer 
Cells 
Our lab has recently shown that knocking down miR-655 expression with 
morpholino oligos significantly reduces the function that COX-2 plays in breast cancer 
progression (Majumder et al., 2012). When the expression of miR-655 is knocked down, 
MCF-7-COX-2 and SKBR-3-COX-2 cell lines show a significant decrease in ability to 
invade, migrate, and proliferate. Since our laboratory has and is currently looking at the 
role of knocking down miR-655, this study looked at the consequences of miR-655 
overexpression in the human breast cancer cell lines MCF-7 and SKBR-3. 
MCF-7 and SKBR-3 breast cancer cells, which express very little miR-655, were 
transfected via nucleofection with either the pCMV-MIR mock vector (control empty 
vector) or the miR-655 Expression Plasmid.  
 To determine if the transfection was successful, miRNA was isolated from the 
cells and analysis of miR-655 expression was performed by quantitative real-time PCR 
(with Taqman probes). Relative fold changes were normalized to internal control RNU44. 
MCF-7 cells transiently transfected with the miR-655 expression plasmid exhibited a 
1000–10,000 fold increase in miR-655 expression in comparison to the parental cell line, 
and a 100-1000 fold increase in comparison to the mock transfected cell line (Figure 13 
(A)). SKBR-3 cells transiently transfected with the miR-655 expression plasmid 
exhibited a 10,000-100,000 fold increase in miR-655 expression in comparison to the 
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parental cell line, and a 1000-10,000 fold increase in comparison to the mock transfected 
cell line (Figure 13 (B)). Transfection with the miR-655 expression plasmid was 
therefore successful.  
3.5.2 MiR-655 Expression Increases the Ability of MCF-7 and SKBR-3 Cells to 
Migrate and Invade 
 To determine the effect that miR-655 overexpression plays in cellular migration 
and invasion, cell lines were separately plated on the top chamber of transwell migration 
inserts 72 hours post transfection and allowed to migrate for 24 hours (Figure 14 (A)). 
Cell lines were also plated on the top chamber of transwell inserts coated with Matrigel 
72 hours post transfection and allowed to invade for 48 hours (Figure 14 (B)). The 
bottom chambers contained 2% FBS. The cells on each membrane were counted 
manually. The cells that were transfected with the miR-655 Expression Plasmid showed 
a significant increase in ability to migrate and invade. Even though SKBR-3-655 did 
show an increase in invasion, it was not statistically significant.  Based on these results, 
it can be suggested that miR-655 expression plays a role in making breast cancer cells 
more aggressive in their ability to migrate and invade.  
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Figure 13. MCF-7 cells (A) and SKBR-3 cells (B) transfected with miR-655 
expression plasmid significantly overexpress miR-655. Cells were transiently 
transfected using either a mock (empty) or a miR-655 expression plasmid (supplied from 
Origene) by nucleofection. Seventy-two hours post-transfection miRNA was isolated 
from the cells and analysis of miR-655 expression was performed by quantitative real-
time PCR (with Taqman probes). Results presented in relative fold change (2-ΔΔCT 
method). Relative fold changes were normalized to internal control RNU44. (A) MCF-7 
cells transiently transfected with the miR-655 expression plasmid exhibited a 1000–
10,000 fold increase in miR-655 expression in comparison to the parental cell line. (B) 
SKBR-3 cells transiently transfected with the miR-655 expression plasmid exhibited a 
10,000-100,000-fold increase in miR-655 expression in comparison to the parental cell 
line. The data are represented as mean +/- standard deviation (SD) for three independent 
experiments. (*) indicates significant difference (p<0.001). The values for the parental 
cell lines were taken as one.  
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Figure 14. Introduction of miR-655 increases migration and invasion of MCF-7 and 
SKBR-3 cells. (A) Cell lines were separately plated on the top chamber of transwell 
migration inserts 72 hours post transfection and allowed to migrate for 24 hours. (B) Cell 
lines were separately plated on the top chamber of transwell inserts coated with Matrigel 
72 hours post transfection and allowed to invade for 48 hours. The bottom chambers 
contained 2% FBS. The cells on each membrane were counted manually. (*) Indicates 
significant difference (p<0.05). The data represent triplicates +/- standard deviation (SD) 
for three independent experiments normalized to the parental cell line. The values for the 
parental cell lines was taken as 1. 
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3.6 Introduction of miR-655 Increases the Proliferation of MCF-7 Human Breast 
Cancer Cells 
BrdU colorimetric assay was performed to determine the effect of miR-655 
overexpression on MCF-7 and SKBR-3 proliferation.  BrdU incorporation is presented 
as an absorbance value at 370nm (Figure 15) and the experiment was carried out in 
triplicate. MCF-7 cells transiently transfected with miR-655 (MCF-7-655) exhibited a 
significant increase in cellular proliferation in comparison to the parental MCF-7 cell 
line (Figure 15 (A)). SKBR-3 cells transiently transfected with miR-655 (SKBR-3-655) 
showed no difference in cellular proliferation in comparison to the parental SKBR-3 cell 
line (Figure 15 (B)).  	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Figure 15. Introduction of miR-655 increases the proliferation of MCF-7 human 
breast cancer cells. Seventy-two hours post transfection with either the mock (empty) or 
the miR-655 expression plasmid and cell proliferation ELISA was performed using 
transiently transfected MCF-7 cells (A) and SKBR-3 cells (B). BrdU incorporation is 
presented as an absorbance value at 370nm.  (A) MCF-7 cells transiently transfected 
with miR-655 (MCF-7-655) exhibited a significant increase in cellular proliferation in 
comparison to the parental MCF-7 cell line. (B) SKBR-3 cells transiently transfected 
with miR-655 (SKBR-3-655) showed no difference in cellular proliferation in 
comparison to the parental SKBR-3 cell line. However, the proliferative ability was 
significantly higher than the mock-transfected cells.  The data are represented as mean 
+/- standard deviation (SD) for three independent experiments. Different superscripts 
indicate statistically significant differences, while shared superscripts indicate no 
significant difference (p < 0.05).  
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3.7 Introduction of miR-655 Increases the Expression of COX-2 in MCF-7 and 
SKBR-3 Human Breast Cancer Cells 
To determine the effect that miR-655 has on COX-2 expression, RNA and protein 
were isolated from transfected cells for analysis of mRNA expression by quantitative 
real-time PCR and protein expression by Western blot analysis. COX-2 mRNA 
expression by quantitative real-time PCR (with Taqman probes) was normalized to the 
internal control GAPDH and was carried out in triplicate (Figure 16 (A)). MCF-7-655 
significantly overexpresses COX-2 mRNA relative to the parental and mock cell lines 
(Figure 16 (A)). MCF-7-655 expressed COX-2 mRNA at a 4 fold increase in comparison 
to the MCF-7 parental cell line, and a 3 fold increase in comparison to the mock 
transfected cell line (MCF-7-mock). Even though the data for SKBR-3 are the result of a 
single experiment, SKBR-3-655 appeared to express COX-2 mRNA at ~1800 increase 
level in comparison to the mock and parental cell lines (Figure 16 (B)).   
Protein was isolated from MCF-7, MCF-7-mock and MCF-7-655 for COX-2 
protein expression by Western blot. MCF-7-COX-2 protein was used as a positive 
control and GAPDH was used as a loading control. MCF-7 transfected with the miR-655 
expression plasmid appeared to overexpress COX-2 at the protein level as well, however 
this needs to repeated and quantified with densitometry.  
 Based on these results it can be concluded that miR-655 plays a role in increasing 
COX-2 expression in MCF-7 human breast cancer cells.   
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Figure 16.  Introduction of miR-655 in MCF-7 and SKBR-3 human breast cancer 
cell lines increases COX-2 expression. Cells were transiently transfected using either a 
mock (empty) or a miR-655 expression plasmid (supplied from Origene) by 
nucleofection. Seventy-two hours post-transfection RNA was isolated from the cells for 
analysis of COX-2 mRNA expression by quantitative real-time PCR (with Taqman 
probes) (A & B). Results presented in relative fold change (2-ΔΔCT method). Relative fold 
changes were normalized to internal control GAPDH. (A) The data are represented as 
mean +/- standard deviation (SD) for three independent experiments. Different 
superscripts indicate statistically significant differences, while shared superscripts 
indicate no significant difference (p < 0.001). MCF-7-655 significantly overexpressed 
COX-2 mRNA relative to the parental and mock cell lines. (B) The data for SKBR-3 are 
the result of a single experiment (n=1), revealing that SKBR-3-655 cells show an up-
regulation of COX-2 mRNA expression. (C) Protein was isolated from MCF-7, MCF-7-
mock and MCF-7-655 for COX-2 protein expression by Western blot. MCF-7-COX-2 
protein was used as a positive control and GAPDH (housekeeping gene) was used as a 
loading control (n=1).   
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CHAPTER FOUR: SUMMARY AND DISCUSSION 
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4.1 Summary 
Based on the results presented in Chapter 3, the following remarks can be made: 
• The migratory and invasive capacities of the COX-2 disparate cell lines went 
hand in hand with COX-2 expression.  
• Quantification of miR-655 expression and COX-2 mRNA and COX-2 protein 
revealed that COX-2 expression is associated with an up regulation of miR-655. 
•  Expression of miR-655 was markedly inhibited by treating MCF-7-COX-2 and 
SKBR-3-COX-2 cells with a COX-2 inhibitor (NS398) or an EP4 antagonist 
(ONO-AE3-208), indicating that the expression depended on both COX-2 and 
EP4 activity.  
• MCF-7, MCF-7-COX-2, SKBR-3 and SKBR-3-COX-2 cell lines grown as 
tumorspheres significantly overexpressed COX-2 in comparison to the same cell 
lines grown as a monolayer.  
• MCF-7, MCF-7-COX-2, and SKBR-3 cell lines grown as tumorspheres 
significantly overexpressed miR-655 in comparison to the same cell lines grown 
as a monolayer.  
• MCF-7 and SKBR-3 cell lines transfected with a miR-655 Expression Plasmid 
showed a significant increase in miR-655 expression. The transfected cell lines 
also showed an increase in migratory and invasive capacity. MCF-7-655 also 
showed an increase in proliferation in comparison to both the parental and mock 
transfected cell lines.  
Original contribution: The COX-2 regulated miRNA, miR-655, is implicated in the 
stimulation of breast cancer cell migration, invasion and tumorsphere formation.  
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Figure 17. Speculated Mechanism of COX-2 and miR-655 signaling in human 
breast cancer cell lines.  COX-2 overexpression leads to the production of endogenous 
PGE2, which binds to the EP receptors to elicit its response. PGE2 induced activation of 
the EP receptors may result in the recruitment of the NF-kB transcription factor binding 
to the miR-655 gene (Shin et al., 2000 and Bhattacharjee et al., 2009). MiR-655 may 
then target IFN-gamma, which may lead to a further up-regulation of COX-2 expression 
(Nares, 2011).  
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4.2 Overview 
Present studies on miR-655 and reports on other miRNAs in the literature have 
revealed that certain miRNAs play important roles in breast cancer cell proliferation, 
invasion and migration (Martello et al., 2010 and Shi et al., 2010). These miRNAs may 
serve as potential biomarkers for breast cancer. Once validated, miRNAs could have 
significant clinical impact by allowing clinicians to monitor disease progression by 
measuring circulating miRNAs that are stable in the blood (Andorfer et al., 2011). 
MiRNA signatures may be used as novel prognostic indicators that will help in the 
development of improved personalized therapy for breast cancer. 
The distinction between miRNAs and other RNA interfering molecules (i.e. 
siRNA/shRNA) is that they are natural small RNAs synthesized in the body and are 
present from early development to any disease stage (Bartel, 2004). These miRNAs can 
target hundreds of mRNAs due to their imperfect complementarity to their target mRNA. 
A single miRNA therefore can affect multiple targets, regulating several genes on a 
similar pathway and a whole network of interacting molecules (Bartel 2004 and 2009). 
Therefore, it is a challenge to determine the mechanisms of how COX-2 regulates miR-
655, and vice versa, in breast cancer cells.  
4.3 The Role of COX-2 in Breast Cancer Progression 
 In the present study, stable transfection of COX-2 into two poorly migratory and 
invasive cell lines, MCF-7 and SKBR-3 stimulated their migratory and invasive capacity 
both under serum free and FBS stimulated conditions. These findings are in support of 
earlier data from this and other laboratories. 
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 Our laboratory has shown that COX-2 expression by breast cancer cells in both 
murine and human breast cancer models promotes tumor progression by multiple 
mechanisms. These include the inactivation of host anti-tumor immune cells by tumor-
derived PGE2 (Parhar and Lala, 1985, 1986), enhanced cell migration and invasiveness 
(Rozic et al., 2001, Timoshenko et al., 2003), enhanced tumor-associated angiogenesis 
(Rozic et al., 2001), an up regulation of VEGF-C (Timoshenko et al., 2006) and thereby 
lymphangiogenesis and lymphatic metastasis (Bhattacharyya et al., 2010) as well as 
VEGF-C mediated stimulation of cancer cell migration (Timoshenko et al., 2001). 
Furthermore, it was shown that COX-2 induced migration as well as VEGF-C up-
regulation (Timoshenko et al., 2003) was mediated at least in part by endogenous PGE2 
acting primarily via the EP4 receptor (Timoshenko et al., 2006). 
 Recently, in a high COX-2 expressing murine breast cancer cell line C3L5, 
selected from lung metastasis in a spontaneous mammary tumor, COX-2 was shown to 
up-regulate the lymphangiogenic factors VEGF-C and VEGF-D in vitro and in vivo 
primarily via EP4 receptor activation. In this tumor model, therapy with the COX-2 
inhibitor Celecoxib, as well as an EP4 antagonist ONO-AE3-208, abrogated growth of 
the primary tumors, tumor-associated angiogenesis and lymphangiogenesis, as well as 
metastasis to the lymph nodes and the lungs (Xin et al., 2012).  
 In both MCF-7-COX-2 and SKBR-3-COX-2 breast cancer cell lines, earlier data 
by Majumder et al. (AACR 2012, abstract) revealed that the enhanced migratory and 
invasive capacity of these cells was dependent on COX-2 and EP4 activity. Both the 
COX-2 inhibitor NS-398 and EP4 antagonist ONO-AE3-208 inhibited their migratory 
and invasive capacity.  
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 Several laboratories have examined mechanisms underlying the roles of COX-2 
in promoting breast cancer cell invasion. For example, Singh et al. (2005) transfected 
COX-2 cDNA into the highly invasive estrogen-independent human breast cancer cell 
line MDA-MB-231 to show that the migratory and invasive capacity of the cells were 
stimulated further, in association with an increased expression of prourokinase 
plasminogen activator (pro-uPA). UPA can activate plasmin, which in turn can activate 
matrix metalloproteinases (MMPs) capable of degrading basement membrane 
components. Singh et al. (2005) illustrated a mechanism of COX-2 promotion of cellular 
invasion by showing that the level of pro-uPA was significantly higher (approximately 5-
fold) in COX-2 transfected MDA-MB-231 cells compared to untransfected MDA-MB-
231 cells via Western blotting. Additionally, they showed that increased COX-2 activity 
correlates with uPA in an in vivo mouse model of breast cancer metastasis to bone.  
As previously mentioned, in order for cancer cells to migrate and invade and 
therefore metastasize, the cells must digest the basement membrane components (e.g., 
laminin, collagen IV, entactin and heparin sulfate proteoglycan) and the ECM, typically 
requiring the secretion and activation of MMPs. In particular, the gelatinases (MMP-2 
and MMP-9) have been associated with high potential for metastasis in several human 
cancers including breast (Barsky et al., 1983 and Pacheco et al., 1998). Takahashi et al. 
(1999) have shown that Hs578T breast cancer cells transfected with COX-2 resulted in 
the activation of MMP-2. Sivula et al. (2005) also found increased COX-2 expression in 
breast cancer specimens in association with increased levels of MMP-2. Larkins et al. 
(2006) have likewise shown that inhibition of COX-2 using NS-398, decreases breast 
cancer cell motility and invasion due to the decrease in MMP expression.  These studies 
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together reveal that the role of COX-2 in modulating the expression of MMP-9 and 
MMP-2 may be an important component of the molecular mechanisms by which COX-2 
promotes cellular invasion and migration.  
 
4.4 The Role of COX-2 in the Induction of miR-655 Expression 
 Our discovery of the induction of miR-655 by COX-2 and its role in promoting 
breast cancer aggressiveness presents a novel mechanism in breast cancer progression. A 
possible mechanism for the induction of miR-655 by COX-2 is that the gene encoding 
miR-655 may be the target of certain transcription factors that are activated in response 
to COX-2 in aggressive breast cancer cells. Whether downstream effectors in the 
prostaglandin signaling pathway are binding to and activating the promoter of miR-655, 
remains to be examined. It is also possible that downstream effectors in the prostaglandin 
signaling pathway bind to processing complexes within the miRNA biogenesis pathway, 
such as Drosha/DGCR8 or Dicer, leading to increased miR-655 expression.  
 In a study similar to ours, Shin et al. (2010) identified two miRNAs, miR-16 and 
miR-21, that were up-regulated in nicotine induced gastric cancer. They showed that the 
up-regulation of miR-16 and miR-21 were dependent on the transcription factor nuclear 
factor-kappa B (NF-kB), which induces COX-2 expression. Using bioinformatics, they 
determined that the miR-16 and miR-21 genes are in fact the direct targets of NF-kB. 
Furthermore, they demonstrated that antagonists of the EP2 and EP4 receptors attenuated 
nicotine activation of NF-kB. Additionally, it has been shown that COX-2 mediated up-
regulation of VEGF-C, due to endogenous PGE2 induced activation of the EP receptors, 
results from the recruitment of the NF-kB transcription factor binding to the VEGF-C 
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promoter site (Bhattacharjee et al., 2009). It is possible that miR-655 up-regulation by 
COX-2 results from NF-kB binding to the corresponding gene of miR-655 (Figure 19). 
To test this hypothesis, we would have to look at the transcription factor-binding sites in 
the miR-655 gene to determine if the NF-kB-binding site is present.  
4.5 The Role of COX-2 and miR-655 Expression in Inducing the Tumorsphere 
Formation 
This study has shown that COX-2 expression and miR-655 expression are both 
implicated in tumorsphere formation. Since COX-2 and miR-655 were significantly 
overexpressed in cells grown as tumorspheres compared to cells grown as a monolayer, 
it is likely that both play a role in maintaining the CSC in vitro. The role of COX-2 in the 
maintenance of the stem-like state has also been reported for in mesenchymal stem cells 
involved in osteogenesis (Yoon et al., 2010). Similarly Liou et al. (2007) state that COX-
2 derived PGE2 protects embryonic stem cells from apoptosis. 
COX-2 overexpression associated with tumorsphere formation can be explained 
by two possibilities: (1) Sphere-initiating cells can survive under stress and hypoxia, both 
of which can up-regulate COX-2 and COX-2 activity in turn can promote their expansion 
and survival. Colony formation in ultra-low attachment plates maybe subjected to stress 
and hypoxia.  In support of this hypothesis it has been shown that direct transcriptional 
up-regulation of COX-2 by the hypoxia inducible factor (HIF)-1 promotes colorectal 
tumor cell survival and enhanced HIF-1 transcriptional activity during hypoxia (Kaidi et 
al., 2006). (2) The CSC, even if rare in a cancer cell line, is high COX-2 expressing to 
start with and the COX-2 expressing CSC then expands as a colony. Singh et al. (2010) 
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speculated that the rare cells highly expressing COX-2 from MCF-7 tumorspheres induce 
the CSC state. This hypothesis could only be tested if the rare high COX-2 expressing 
cancer cells could be separated out by cytofluorometry and subsequently have their CSC 
activity measured. While such fluorometry is yet to be developed, the design could be 
similar to the measurement of Aldefluor activity used as a CSC marker to separate out 
ALDH-1 positive cells.  
 Since there is a significant up-regulation of miR-655 in tumorspheres with a 
concomitant up-regulation of COX-2 expression, this miR-655 up-regulation may be the 
consequence of COX-2 expression. On the other hand, the reverse cannot be ruled out 
since MCF-7-655 cells also showed increased COX-2 expression.   
Interestingly, MCF-7 and MCF-7-COX-2 cells formed more spherical 
tumorspheres in comparison to SKBR-3 and SKBR-3-COX-2 cells, which formed 
irregular spheres. One main difference between the MCF-7 and SKBR-3 cell lines is that 
SKBR-3 overexpresses HER-2. However, breast cancer cell lines BT474 and MDA361 
also have amplified HER-2 expression and they still form morphologically spherical 
spheres similar to MCF-7 cells (Wang et al., 2011). Therefore, HER-2 may not be the 
reason why SKBR-3 cells formed irregular spheres. Other laboratories have reported the 
formation of spherical SKBR-3 tumorspheres (Fengyan et al., 2007), however, in our 
hands we were unable to get ideal spheres.  Due to the heterogeneity of cell lines, it is 
possible that the progeny of the stem-like cells may also be heterogeneous in their 
growth rate. This may explain the irregular formation of tumorspheres in vitro in cell 
lines such as SKBR-3 and SKBR-3-COX-2. In conclusion, the morphology of the 
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spheres formed may be context dependent or a result of the heterogeneity of a breast 
cancer cell line.  
We have established that COX-2 plays a role in inducing miR-655 expression 
and tumorsphere formation, but the exact mechanisms remain to be investigated. Wang 
et al. (2011) showed that transforming growth factor-β (TGF-β) regulates the sphere-
initiating stem cell-like feature in breast cancer cells through miR-181. Similarly, it is 
possible that COX-2 regulates the sphere formation via miR-655. To test this hypothesis, 
several approaches should be utilized. First, we would have to use a cell line with stable 
miR-655 expression in the absence of COX-2 expression and grow tumorspheres in 
order to determine if miR-655 overexpression alone could induce spheres in non-COX-2 
expressing cells. Secondly, we would have to treat COX-2 negative cells, such as MCF-7, 
with exogenous PGE2 and EP4 agonist and observe if these breast cancer cells could 
form spheres more effectively and if miR-655 is simultaneously up-regulated. Finally, it 
would be important to look at the downstream targets of miR-655 to see if any of the 
genes that are inhibited by miR-655 play a role in influencing the sphere forming ability 
of breast cancer cells.  
One important target of miR-655, as well as the second COX-2 up-regulated 
miRNA miR-526b, is the CPEB-2 tumor suppressor gene. This gene is a senescence- 
associated molecule. CPEB-2 null mice do not survive and the embryonic fibroblasts in 
these mice fail to mature (Groisman et al., 2006). The role of the CPEB-2 gene could be 
tested by down-regulating it in MCF-7 cells or up-regulating it in MCF-7-COX-2 cells 
and then looking at the subsequent efficiency of tumorsphere formation.  
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One miRNA known to play a role in maintaining the stem cell phenotype in 
embryonic cells is miR-302 (Lin et al., 2008). MiR-302 is expressed most abundantly in 
slow-growing human embryonic stem cells, and quickly decreases after cell 
differentiation and proliferation. Lin et al. (2008) transfected miR-302 into several 
human cancer cell lines. The miR-302-transfected cells not only expressed many key 
stem cell markers, such as Oct3/4, Sox2, and Nanog, but also had a highly demethylated 
genome similar to a reprogrammed zygotic genome. These miR-302-transfeted cells also 
maintained pluripotency since they could differentiate into distinct tissue cell types, such 
as neuron, chondrocyte, fibroblast, and spermatogonia like primordial cells (Lin et al., 
2008). In our study it would be very interesting to examine the expression of these stem 
cell markers in MCF-7-655 and SKBR-3-655 cells.  
4.6 The Effect of COX-2 Inhibition and EP4 Antagonism on miR-655 Expression 
In both MCF-7-COX-2 and SKBR-3-COX-2 human breast cancer cell lines, 
treatment with the COX-2 inhibitor (NS-398) and the EP4 antagonist (ONO-AE3-208) 
significantly decreased the expression of miR-655. This indicates that the expression of 
miR-655 in human breast cancer cell lines is dependent on both COX-2 and EP4 activity. 
Both EP2 and EP4 are linked with a Gs protein and thus activation of these 
receptors leads to an increase in intracellular cAMP followed by activation of protein 
kinase A (PKA). In addition, EP4 activation can also stimulate the PI3K/Akt pathway 
(Sugimoto et al., 2007) to promote PGE2 dependent cell survival. In order to determine 
the role of the EP4 receptor in miR-655 expression we would have to examine whether 
the up-regulation of miR-655 depends on the stimulation of the PKA or PI3K/AKt 
pathways. It is possible that components of one or both of these pathways play a role in 
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up-regulating miR-655 expression. 
There is compelling epidemiological evidence that intake of NSAIDs, including 
COX-2 inhibitors, leads to significant risk reductions for the development of cancers in 
various organs including the breast (Harris et al., 2003 and 2009). Since COX-2 
inhibitors cause cardiovascular side effects (Fitzgerald, 2004) alternative and safer 
therapies need to be tested in preclinical models. 
 Recent studies have demonstrated that the EP4 antagonist ONO-AE3-208, but not 
EP1 antagonist ONO-8713, was highly and equally effective as a COX-2 inhibitor 
(Celecoxib) in inhibiting primary tumor growth and tumor-associated lymphangiogenesis 
and lymphatic metastasis in vivo. Furthermore, ONO-AE3-208 produced no drug-related 
toxicities (Xin et al., 2012).  
Since EP4 has been shown to promote breast cancer progression and it may have 
a role in inducing miR-655 and thereby the CSC phenotype, we suggest that EP4 
antagonism may prove to be a safe therapy in breast cancer patients in preventing and 
reducing metastasis in combination with other agents. 
4.7 The Effect of miR-655 Expression on COX-2 Expression 
 We have shown that miR-655 up-regulates COX-2 expression in MCF-7 breast 
cancer cells, however the underlying mechanisms remain unknown.  
Literature reporting on the role of miR-655 is very limited. One study suggests 
that miR-655, amongst other miRNAs, regulate amyloid precursor protein expression in 
vitro, therefore having a potential role in Alzheimer’s disease progression (Delay et al., 
2011). One interesting study by Nares (2011) used microarrays to identify differentially-
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expressed miRNA profiles of periodontal diseased tissues and found that miR-655 
targets the 3’ UTR of interferon-gamma (IFN-gamma), an inflammatory cytokine present 
in the tumor microenvironment. Several studies report an anti-inflammatory role of IFN-
gamma as it has been shown to suppress COX-2 transcription in tissues such as the 
placenta (Hanna et al., 2004) and in vascular lesions (Deng et al., 2005). Therefore, miR-
655 could be inhibiting IFN-gamma leading to an up-regulation of COX-2 expression 
(Figure 19). However, IFN-gamma has also been shown to up-regulate a variety of pro-
inflammatory mediators such as interleukin (IL)-12, tumor necrosis factor-α (TNFα) and 
inducible nitric oxide synthase (iNOS) (reviewed by Muhl and Pfeilshofter, 2003). 
Therefore the role of this cytokine in inflammation is ambiguous. 
 Another mechanism by which miR-655 could up-regulate COX-2 expression is 
via the down-regulation of DNA methyltransferase (DNMT). DNMTs epigenetically 
silence gene expression by methylation. Fang et al. (2012) showed that miRNAs of the 
miR29 family induce COX-2 expression in lung epithelial cells by regulating DNMTs, 
and this is worth investigating in our future studies.   
4.8 The Role of miR-655 in the Promotion of Migration, Invasion and Proliferation 
of MCF-7 and SKBR-3 Breast Cancer Cells 
 Our laboratory has recently shown that knocking down miR-655 expression with 
morpholino oligos significantly reduced COX-2 mediated function in breast cancer 
progression (Majumder et al., 2012). When the expression of miR-655 is knocked down, 
MCF-7-COX-2 cells show a significant decrease in their ability to invade, migrate, and 
proliferate and SKBR-3 showed noted variability. Similarly, as presented here, when 
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miR-655 is overexpressed, MCF-7 and SKBR-3 cell lines showed an increase in ability 
to migrate and invade. The introduction of miR-655 also increased the ability of MCF-7 
cells, but not SKBR-3 cells, to proliferate. There are several explanations for this 
difference. The increase in proliferation of MCF-7-655 cells may be context dependent 
or cell line specific and needs to be further investigated in other breast cancer cell lines. 
Another possibility as to why there was no difference seen in SKBR-3-655 proliferation 
is that the incubation period with BrdU needs to be longer than six hours, since in culture 
SKBR-3 is a relatively slower growing breast cancer cell line.  
 If miR-655 increases the expression of COX-2 as discussed earlier then the 
increase in migration, invasion and proliferation seen in the transfected cell lines is likely 
the result of COX-2 up-regulation. As discussed previously, it is well documented that 
COX-2 increases migration, invasion and proliferation in human breast cancer cells 
(Timoshenko et al. 2003, Rozic et al. 2001, Sobolewski et al. 2010, and Singh et al. 
2005).  
4.9 Clinical Implications and Significance 
MiRNAs can be easily extracted from nearly every cell and tissue type due to 
their high resistance to degradation and their small size. Circulating miRNAs can easily 
be measured in whole blood or serum (Andorfer et al., 2011). Identification of miRNAs 
up-regulated in human breast cancer that are associated with the CSC phenotype and 
COX-2 overexpression are promising for use as prognostic markers for screening, 
monitoring, and therapeutic responses in the clinic. 
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COX-2 inhibitors and EP4 antagonists have been successfully utilized to abrogate 
tumor growth, tumor-associated angiogenesis, lymphatic and lung metastasis in a COX-2 
overexpressing murine breast cancer model (Xin et al., 2012). Thus, EP4 may prove to 
be a safe target in the clinic for preventing and mitigating lymphatic metastasis of breast 
cancer in combination with other agents. 
4.10 Possible Limitations 
 One important limitation of the present study design is the use of a limited 
number of cell lines. Although similar results were seen in both the MCF-7 and SKBR-3 
breast cancer cell lines, results varied somewhat, especially with respect to proliferation. 
In order to establish a universal role of miR-655 in COX-2 mediated breast cancer 
progression it is important to examine its expression and function in other breast cancer 
cell lines and in vivo. 
 Another limitation of this study is that the CSC phenotype was only analyzed 
using a single assay, the tumorsphere formation assay. In order to strengthen our present 
results it would be helpful to revalidate the CSC phenotype of our cells by testing for 
other possible stem cell markers (e.g., Oct-4, Nanog, Sox-2 and CD44+/CD24- ). 
4.11 Future Directions  
4.11.1 Mechanism in COX-2 and miR-655 signaling? 
 The present study was unable to discern the mechanisms responsible for COX-2 
up-regulation of miR-655 expression and vice versa in MCF-7 and SKBR-3 human 
breast cancer cells. Our results show that COX-2 up-regulation leads to miR-655 
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expression and likewise miR-655 up-regulation leads to COX-2 overexpression. Future 
studies are needed to examine this relationship, including functional testing of the 
predicted miR-655 target genes (i.e. CPEB2, TP53 etc.). Treating breast cancer cells with 
exogenous PGE2 or EP4 agonist (PGE-alcohol) and looking for a possible up-regulation 
in miR-655 and increased spheroid formation would also help to elucidate the 
mechanism of action of COX-2 and miR-655 expression.  
4.11.2 Future in vivo experiments 
Additional work will be performed in vivo to strengthen the acquired results and 
thereby the level of confidence in the hypothesis being tested. In complementary studies, 
Dr. Mousumi Majumder will assess the effects of miR-655 knockdown in MCF-7-COX-
2 cells and overexpression of miR-655 in MCF-7 cells on the lung-metastatic ability in 
NOD/SCID/GUSB null mice (in collaboration with Dr. David Hess, Roberts Institute). 
Our laboratory also plans to analyze the expression of miR-655 in human breast cancer 
tissues and blood samples.  
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Figure A1. MicroRNA Overexpression Plasmid. A vector map of the MicroRNA 
pCMV6-MiR Expression Plasmid (OriGene). The expression of miRNA is driven by the 
CMV promoter and with human growth factor 1 poly(A) tailing signal. 
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Figure A2. COX-2 overexpression increases the incidence and size of spheroids. 
Passage zero (A) shows that incidence and size of spheroids in COX-2-expressing MCF-
7 and SKBR-3 cells. (B) and (C) Serial passage of spheroid-derived cells from MCF-7-
COX-2 shows increased spheroid-forming capacity both in number (B) and sizes (C) . P-
values for each passage are <0.001. (Majumder M et al., 2012.) 
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